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ABSTRACT
Campylobacter jejuni is a major cause of gastroenteritis in humans. The capsule
of some species contains unique modified heptoses. Heptose modification and novel
epimerases and reductases were identified for C. jejuni NCTC11168 and 18-176. We
hypothesized that heptose modifying enzymes in C. jejuni have specific catalytic residues
that allow for substrate and product specificity. Substrate synthesis, structural modeling,
point mutations, and enzymatic analysis have been applied to map the active sites.
Putative catalytic residues showed substrate and/or product specificity. The epimerases
structures were solved by crystallography done by our collaborator. We also
hypothesized that synthesis of the modified heptoses is important for biofilm formation.
In vitro experiment of C. jejuni NCTC11168 showed that the heptose modefication
biosynthesis mutants have a significant reduction in biofilm formation under aerobic
conditions.
This project has provided essential information about the structure and
mechanism of heptose modifying enzymes. It also will emphasize their importance in
some C. jejuni virulence properties such as biofilm formation.

Keywords: Campylobacter jejuni, Modified heptose, Epimerase, Reductase, Structure,
binding site, Biofilm.
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CHAPTER 1- INTRODUCTION
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1.1.

Campylobacter jejuni:

1.1.1. History and taxonomy:
In 1886, Theodor Escherich observed non-culturable spiral bacteria in a stool
sample from a patient with diarrhea (48). Since then, the same organism has been
frequently observed in bovines and ovines. Two decades after Escherich’s observation,
McFaydean and Stockman were able to isolate vibrio-like bacteria from aborted bovines
(113). In 1919, several investigations conducted by Smith and Taylor on bovines’
abortions in the USA led to the isolation of spiral bacteria. After confirming that these
were the same as the vibrio-like bacteria isolated by McFaydean and Stockman, they
proposed the name Vibrio fetus (155). In 1931, Johns et al isolated a dysentery related
bacterium that they called Vibrio jejuni (52). The first human infection was reported in
1938, from an outbreak of diarrhea caused by contaminated milk that affected 355
individuals. V. jejuni was observed in most of the patients fecal samples (102). V. jejuni
was then renamed as Campylobacter jejuni, derived from Greek word for the curved rod,
in 1963 by Sebald and Ve´ron (153).
1.1.2. General characteristics:

C. jejuni is a spirally curved gram-negative bacteria 0.5 to 8 μm long and 0.2-0.5
μm wide (101). It has rapid darting and spinning motion mediated by single polar or
bipolar flagella. Biochemically, C. jejuni is catalase and oxidase positive, and urease
negative. C. jejuni requires microaerobic conditions for growth, nitrogen-rich atmosphere
with 5% oxygen and 10% carbon dioxide (101). As a source of energy, it utilizes amino
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acids, which are considered the most important source of carbon, and tricarboxylic acid
cycle intermediates (100, 127, 161). The best temperature range for growth is 34-44C,
with an optimal temperature of 42C. Under stressful conditions, such as in cases of
insufficient nutrition, temperature variation, or osmotic shock, C. jejuni tends to
transform into coccoid form. Coccoids are a viable but not culturable form of bacterial
cells that are metabolically active (132). The genome of C. jejuni is characterized by a
circular chromosome of 1.6 megabases in size with 30.6% G+C content (135).

1.2.

Epidemiology and pathogenesis:

Campylobacters have been recognized as an important cause of human enteritis.
Among ten species, C. jejuni and C. coli were the cause of 95% of the enteritis cases, of
which 90 % were caused by C. jejuni. It is a major bacterial cause of food-borne
gastrointestinal infection, known as campylobacteriosis. C. jejuni is the third most
common cause of diarrhea after E. coli and rotavirus in developing countries (5).
Campylobacteriosis cases in developing countries are most common in children and
immune-compromised individuals. In the developed world, C. jejuni infections are
reported to be more frequent than Salmonella and Shigella infections combined (3). The
incidence of campylobacteriosis has increased over the last ten years (81). According to
the Centers for Disease Control and Prevention, 56 outbreaks of 1,550 illnesses were
reported between 2009 and 2010 in the United States (65). In Canada, 49.69
campylobacteriosis cases per 100,000 population were reported in the Waterloo region,
Ontario, between 1990 and 2004 (85). The highest rate of campylobacteriosis incidence
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within Canada was reported in the province of British Columbia with an annual average
of 38 cases per 100, 000 population during 2005 and 2009 (81).
C. jejuni is naturally found as a commensal in the lumen of poultry intestine, wild birds,
and cattle. A high colonization level was found in the intestinal ceca of chickens, ranging
between 105 to 109 colony forming units (CFU)/g (2, 22). Infections of humans with C.
jejuni result from the consumption of undercooked poultry meat or cross-contamination
with other food during food processing (59). The infection also can be acquired through
the consumption of unpasteurized milk or contaminated water (28, 149).

1.3.

Clinical characteristics:

1.3.1. Induced enteritis and immune response:

C. jejuni infection induces acute inflammatory enteritis. The onset of
campylobacteriosis symptoms starts one to three days following exposure to an
infectious dose as low as 360-800 CFU (24). The symptoms start with abdominal pain,
headache, dizziness, fever, and severe diarrhea. The patient starts having watery
diarrhea, and as the disease progresses, it becomes bloody diarrhea (172). However, the
infection is self-limiting, and it resolves within seven days. The severity of symptoms
varies among different age groups. Infection in early childhood is more prevalent than in
late childhood due to the development of immunity (24, 171, 187).
The intestinal innate immune response plays an important role in fighting against
C. jejuni through the production of cytokines and antimicrobial peptides (190). The
humoral immune response against C. jejuni is important in humans (24, 25, 129). Fecal
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IgA and plasma IgG C. jejuni specific antibodies response were reported (74, 98). The
cellular immune response to C. jejuni is not well understood. C. jejuni can escape killing
by human monocytes and survive intracellularly (68). An in vitro study showed the
survival of C. jejuni 81-176 within vacuoles inside human 28SC monocytes (68). It also
found that C. jejuni mediates apoptosis to the infected monocytes by activating the
programmed cell death pathway (68). However in avian host cells, it was shown that C.
jejuni cannot survive within chicken’s peritoneal macrophages in vitro (128).

1.3.2. Immunological neuromuscular disorders:
1.3.2.1.

Guillain-Barre Syndrome (GBS):

An autoimmune disease known as Guillain-Barre Syndrome is one of the longterm consequences of C. jejuni infection, known as acute inflammatory demyelinating
polyneuropathy. GBS is the most common cause of paralysis with yearly incidence up to
1.7 per 100,000 population (6). Damage to the peripheral nerves is caused by infiltration
of the immune cells and anti-gangliosides antibodies (33). It has been reported that up to
60% of GBS cases have a history of bacterial infection 30 days before the onset of
symptoms (64, 125). Many bacterial and viral infections can result in disease occurrence,
such as C. jejuni, Mycoplasma pneumonia, and Epstein-Barr virus (56, 177). C. jejuni
infection is the most common identified cause due to molecular mimicry on the
lipopolysaccharide (LOS) (188). The LOS in some C. jejuni contains gangliosides mimic
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structures, which induce the generation of antibodies that cross-react with the host
gangliosides causing the disease.
1.3.2.2.

Miller Fisher syndrome (MFS):

In contrast to GBS, Miller Fisher syndrome is a rare neurological disorder. It has
mild clinical symptoms characterized by weakness of eye muscles and loss of full control
of body movements (50). It also can be a consequence of earlier infections, such as
influenza (66). The onset of MFS is often preceded by C. jejuni infection. A study
containing 11 MFS diagnosed patients reported that 63 % of the patients have positive C.
jejuni cultures (150).

1.4.

Virulence factors:

1.4.1. Adhesion and invasion:

In an avian host, C. jejuni colonizes the mucus layer and the crypts of the colon
and the mucosa of the cecum. When humans are infected, the bacteria adhere to the ileum
and colon to facilitate invasion. C. jejuni adhesion to the intestinal cells is essential for
disease occurrence. Greater binding ability was observed in strains isolated from patients
who experienced diarrhea and fever compared to the strains isolated from patients with
no symptoms (49). C. jejuni expresses different adhesins, some of which have been
studied extensively. An outer membrane protein, known as Campylobacter adherence
factor (CadF), has been identified as an adhesin that binds to fibronectin on the
extracellular matrix of INT-407 cells (90). According to in vivo and in vitro analysis, C.
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jejuni lacking CadF are unable to adhere to or invade intestinal cells (122). Fibronectin
binding is involved in the induction of signals that activate microfilaments
polymerization for cell uptake, which suggests that CadF is also important for bacterial
invasion (90). Another adhesin was identified, which is the surface lipoprotein JlpA. It is
involved in C. jejuni adherence to HEp-2 cells (76). JlpA binding results in activation of
the inflammatory response in the host (77). A periplasmic amino acid transporter, Ped1,
was identified as an adhesin. Ped1mutants showed a decrease in adhesion and
colonization to the cells (137). However, since Ped1 is localized in the periplasmic space
of C. jejuni, the mechanism of its interaction with the host is still unknown.
Intracellular C. jejuni have been observed in patients’ samples with diarrhea and
in laboratory cell lines (41). C. jejuni cells need microtubule or microfilament
polymerization for maximal invasion (23, 41). Internalization of C. jejuni is activated by
the functional binding of CadF to fibronectin on the cell surface (90). Some secreted
proteins required for C. jejuni invasion were identified, such as Campylobacter invasion
antigen B (CiaB). The ciaB deficient strains are able to bind host cells, but are unable to
invade them (92). Other virulence factors are found to play a role in C. jejuni adhesion
and/or invasion to host cells including the flagella, Lipooligosaccharide (LOS), and the
capsular polysaccharides (CPS) (18, 41).

1.4.2. Intracellular survival:

One of the most important C. jejuni virulence factors is the ability to survive in
macrophages in a strain dependant manner. Different studies reported that C. jejuni 81-
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176, M129, 2964 strains can survive in human and/or murine macrophages for several
days (43, 68, 86). On the other hand, NCTC11168 strain doesn’t survive beyond a few
hours (184). Intracellular C. jejuni was found to induce proinflammatory responses in
human monocytes. In addition, it was found to mediate cell arrest by the production of
cytolethal distending toxin (CDT) and to induce apoptosis (68, 189). Infected human
monocyte apoptosis was reported to be independent of CDT (154, 189). As reported from
an in vitro experiment of M129 strain, C. jejuni survives in the intestinal cells and results
in deterioration of the cell monolayers (91) .
C. jejuni can also survive within free-living protozoa as a protective
environmental host. Many studies reported the intracellular survival of C. jejuni in
Acanthamoeba, which is a genus of amoeba commonly found in soil and water (29, 152,
176). In fact, a longer survival period of C. jejuni was observed when C. jejuni cells were
inside amoeba compared to being in culture media alone (15, 133). It was also found to
survive at lower temperatures and to replicate inside the amoeba at 37C (14). On the
other hand, studies showed that C. jejuni can only survive extracellularly (30, 44). The
conflict in these findings could be explained by the different experimental techniques and
different C. jejuni and Acanthamoeba strains used in different studies (176).

1.4.3. Biofilm formation:

C. jejuni cells can exist in biofilms to protect themselves and survive under
unfavorable conditions. Biofilm formation protects the bacteria when they are out of the
host, which allow their transition into another host or into food products during food
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processing. The ability of C. jejuni to survive in the environment increases the chance of
chicken colonization and food contamination, and thus human infection through
consumption of this contaminated food. C. jejuni biofilms are found in water distribution
systems and surfaces submerged in an aquatic environment (73). C. jejuni populations
can exist in nature in different forms. They exist in biofilms, which are surface adherent
bacterial populations enclosed by a matrix, known as extracellular polymeric substance
(EPS) (38). The matrix composition is highly variable depending on the microbial species
but it usually contains extracellular DNA, proteins, and polysaccharides (27). C. jejuni
populations also can form aggregates that are not attached to a surface or pellicles at an
air-liquid interface (80). Studies showed that C. jejuni can form a single species or mixed
culture biofilms in the environment (73). Many factors can affect C. jejuni biofilm
formation including a functional flagella, temperature, nutrition, or oxygen concentration
(80, 145, 146). Strains with flagellar structure gene mutations showed a decrease in
biofilm formation and inability to attach to surfaces (145). Other studies showed that
aerobic conditions activate C. jejuni biofilm formation (146). Biofilm formation was
proposed as a virulence factor because it provides protection for the bacterial cells from
environmental stressors and from antibacterial agents (38).

1.4.4. Flagella and motility:

The polar flagella of C. jejuni have a critical role, not only in motility, but also in
secretion, invasion, colonization, and biofilm formation (93, 107, 145). Motility is
required for the bacteria to initiate infection in the host by penetrating the mucus layer in
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the intestine (94). In vivo and in vitro experiments showed that non-flagellated C. jejuni
are not motile and unable to invade cells (179). Equally important, the C. jejuni flagellar
apparatus acts as a secretion system for virulence proteins, such as Cia proteins that are
important for adhesion (93).
More than 40 genes participate in the formation and regulation of the flagellar
structure, which consists of a basal body, hook, and a hollow cylindrical filament. The
building units of the flagella are two structural proteins FlaA and FlaB. Both are
regulated by FlgS/FlgR, a two component system, and sigma factors (σ28, σ54) (67, 105,
185). Transposon mutagenesis experiment found that σ28 and σ54 regulate the
production of FlaA and FlaB respectively. Based on in vitro study of flaA-flaB+ mutants,
expression of FlaA was found to be more significant for motility and invasion of
intestinal cells than FlaB (61). C. jejuni flagellin is heavily glycosylated. This
glycosylation is known to occour through an O-linked glycosylation system. O-linked
glycosylation is important for flagellar filament assembly and motility (62).

1.4.5. Glycosylation:

Protein glycosylation is an essential biological process in all life domains where a
particular protein is modified by the addition of sugar structures. Glycosylated proteins
are essential for multiple cellular functions (121). Bacterial protein glycosylation was
discovered in many organisms after it was thought to exist only in eukaryotes (169).
Many prokaryotes have been found to modify proteins by adding sugars either through
the hydroxyl groups of serine and threonine residues (O-linked), or the amide group of an
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asparagine residue (N- linked) (121). O-linked glycosylation was observed in the pilin
subunit of Neisseria meningitides, the surface layer proteins of Colstridium symiosum and
Streptococcus sanguis as well as in the flagellin of Pseudomonas aeruginosa (26, 119,
120) C. jejuni encodes two glycosylation loci for both glycosylation types, which makes
it an effective model to study bacterial protein glycosylation by constructing knockout
mutants (166). The O-linked glycosylation locus is extremely variable among different
strains of Campylobacter species. C. jejuni flagellin proteins are of the most heavily Oglycosylated bacterial proteins. O-linked glycosylation plays an essential role in the
flagellin assembly and thus the motility of C. jejuni cells (62). The location of the Olinked glycans as exposed moieties on the flagellin indicates a significant potential for
interaction with the host cells. Studies showed that O-linked glycosylation is important
for adhesion, and invasion of the host cells (62). Unlike the O-linked glycosylation loci,
N-linked glycosylation loci is highly conserved among C. jejuni strains and has no
putative phase-variable genes (168). Disruption of the N-linked glycosylation pathway in
C. jejuni significantly reduces adhesion, invasion and colonization of chickens (78, 165).

1.4.6. Lipooligosaccharide (LOS):

The lipooligosaccharide (LOS) and lipopolysaccharide (LPS) are important
virulence factors found in the outer membrane of mucosal gram-negative bacteria (140).
LPS are high molecular weight (High Mr) glyco-lipids composed of oligosaccharide core
attached to lipid A, in addition to surface-exposed repeating units of polysaccharide, Oantigen. On the other hand, LOS are low molecular weight (low Mr) with the same main
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structure of LPS, except that it lacks the O-antigen. Two decades ago, C. jejuni was
considered to contain both LPS and LOS (141). The discovery of the capsular gene
cluster proved that C. jejuni’s high molecular weight polysaccharide is in fact capsule
(84, 135). C. jejuni LOS structure has been extensively studied. Lipid A, the hydrophobic
membrane anchor, has a conserved structure among Gram-ngative bacteria. It consists of
two phosphorylated D-glucosamines in (1-6) linkage and attached acyl chains (104, 126,
142). The oligosaccharide chain has been divided into inner and outer core, based on the
different sugar composition. The inner core structure is conserved among various strains,
containing a backbone of 2-keto-3-deoxyoctulosonic acid (Kdo), two L-glycero-Dmanno-heptoses (L, D-Hep), D-galactose (D-Gal), and terminal D-glucose (D-Glc) (123,
160). The outer core is structurally diverse among C. jejuni strains. To date, the structure
of more than ten C. jejuni serostrains LOS outer core have been identified (10-12, 58,
160, 167). LOS is an important structure for bacterial transition across the intestinal
epithelial cells, and for immune evasion (106, 109). A remarkable feature in the C. jejuni
LOS is that it possesses structures that mimic humans’ peripheral nerves gangliosides.
This mimicry contributes to autoimmune neurological disorders upon infection, such as
GBS and MFS (57, 58, 72, 124, 125).
1.4.7. Capsule polysaccharide (CPS):

Like many other Gram-negative bacteria, C. jejuni possesses capsular
polysaccharide surface structure. The capsular polysaccharide (CPS) is made of high
molecular weight polysaccharides, organized in repeated units of carbohydrates called K-
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antigen. This K-antigen is attached to the outer membrane by a phospholipid anchor. CPS
structures are extremely diverse, not only between different species but also between
different strains within the same species (82). The highly diverse structure makes them a
major component of the classical Penner serotyping system (84). The variation is
attributed to different genetic components and extensive phase variable modifications in
favor of evading the host immune response (148).
C. jejuni CPS acquire unique modifications as different strains express heptoses
of unusual configuration such as, D-altro-, L-gluco-, ido- heptoses (9, 111, 160). Further
heptoses modifications can be acquired in C. jejuni CPS by C6 dehydration to generate 6deoxy-heptose found in 81-176 strain (110). In addition, an O-methyl phosphoramidate
group (MeOPN), which is a rare labile phosphorylated structure, is found attached to the
modified heptose and to different sugar components in multiple strains (114-116).
The K-antigen backbone structures of different C. jejuni strains have been
identified. C. jejuni 81-176 contains repeated units of β-D-N-acetylglucosamine (β-DGlcNAc), α-D-galactose (α-D-Gal), and the modified heptose 6-deoxy-D-altro-heptose.
On the other hand, C. jejuni NCTC 11168 CPS backbone contains repeated units of β-DRibofuranose (D-Ribƒ), β-D-2-acetamido-2-deoxy-β-D-galactofuranose (β-D-GalƒNAc),
-D-glucuronic acid (α-D-GlcpA) with 2-amino-2-deoxyglycerol (GroN), and a modified
heptose 3,6-OMe-L-gluco-heptose (9, 160).
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Figure 1: Schematic representation comparing the CPS structure and the modified
heptoses of C. jejuni 81-176 and NCTC 11168. A. the CPS of C. jejuni 81-176 contains
phospholipid anchor (PL) and attached repeated units of D-GlcNAc (1), D-Gal (2), and
the modified heptose 6-deoxy-D-altro-heptose (H1), represented in chemical structure
underneath. B. the CPS of C. jejuni NCTC 11168 contains repeated units of D-Ribƒ (1),
D-GalƒNAc (2), D-GlcpA (3), and a side branch of modified heptose 3,6-O-Me-L-glucoheptose (H2), represented in chemical structure underneath.
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1.4.7.1.

CPS genetics:

CPS has been recently classified in E. coli into four groups based on genetic and
synthetic properties (181). C. jejuni CPS resemble both group II and III enterobacterial
capsules. Both groups corresponding gene clusters are characterized by two conserved
regions containing genes involved in assembly and transport (region 1, 3), flanking a
major biosynthetic region (region 2) (Figure 2). Region 2 is the strain-specific region that
includes genes encoding the various sugar nucleotide synthetases for the K-antigen (148).
In group III CPS, four conserved genes belong to region 1, kpsE, kpsT, kpsM, and kpsD.
While in C. jejuni there is a fifth gene, kpsF, which could have a regulatory role in the
export of the capsule chain (35, 36). KpsE and KpsD play a role in the translocation of
the polysaccharide chain across the periplasmic space to the outer membrane (8). While
KpsM and KpsT are ABC-transporters involved in transporting the polysaccharide across
the inner membrane to the periplasmic area (131, 139). Region 3 contains two genes,
kpsS and kpsC (84). Homologues kpsS and kpsC genes in group II CPS in E. coli are
involved in attaching the Kdo, which is synthesized by KpsU, to the phosphatidic acid
and subsequently to the polysaccharide’s reducing end (183). However, the lack of kpsU
in C. jejuni suggests that the K-antigen is not linked to the phospholipid via Kdo.
Therefore, kpsS and kpsC could be encoding proteins that are involved in attaching the
polysaccharide into the phospholipid anchor.
In C. jejuni NCTC 11168, the capsular genes cluster was identified in 2000 by a
complete genome sequencing (83, 84). After this discovery, several studies were
dedicated to investigate the function of the genes in CPS biosynthesis and structural
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diversity. The biosynthetic region (region 2) of six C. jejuni strains was studied and
compared to the sequenced strain NCTC 11168 (82). The study revealed that the
structural diversity is related to variation in region 2 of the capsular cluster. Despite the
variations, several genes involved in particular sugar synthesis or modifications were
conserved between several strains, including the heptose synthesis genes, cjj1423c
(hddC), cjj1424c (gmhA2), and cjj1425c (hddA). Genes involved in heptose
modifications were identified in C. jejuni 81-176, cjj1425 (wcaG), cjj1426 (ddahA),
cjj1427 (ddahC), and cjj1430 (ddahB), as well as in NCTC 11168 strain cj1426, cj1427
(wcaG), cj1428 (mlghC), and cj1430 (mlghB) (82, 111). MeOPN synthesis genes
(cj1415c - cj1418c), and two genes (cj1421c and cj1422c) encode transferases for the
addition of MeOPN to D-GalƒNAc and D-α-L-glucoHepp, respectively. In addition,
cj1426c (mlghD) is reported to methylate the 3,6-O-Me-L-gluco-heptose at O6, while
cj1419c could be responsible for the methylation at O3 (Creuzenet lab, unpublished)
(111, 164) (Figure 3).

1.4.7.2.

CPS synthesis:

The synthesis of the capsule has been extensively studied in E. coli for the three
groups. Since C. jejuni capsule resembles group II and III, the synthesis mechanism of
these groups only will be explained in this section (Figure 2). CPS synthesis starts in the
cytoplasm where the phosphosugar nucleotide precursors are polymerized prior to being
exported to the periplasmic space. There, specific surface translocation reactions take
place to export CPS to the cell surface (162).
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While the initiation mechanism of the polysaccharide synthesis remain unknown,
the synthesis process has been shown to take place on the cytoplasmic face of the plasma
membrane (181). A membrane-bound complex, consisting of glycosyltransferases (KfiAD) and Kps proteins, is believed to be the origin of the synthesis process (147). The
elongation of the polysaccharide chain is carried out by the glycosyltransferases at the
non-reducing end in a sequential pattern. The growing polysaccharide chain is then
transported across the inner membrane to the periplasmic space. The Kdo attachment to
the reducing end of the polysaccharide in group II CPS is believed to occur before the
export step. This fact was concluded from the accumulation of the polysaccharides
lacking Kdo in the cytoplasm due to mutations in KpsC and KpsS (148). However in
group III and C. jejuni CPS where there is no Kdo, it is believed that KpsC and KpsS are
involved in attaching the polysaccharide chain to the phospholipid (84). The translocation
of the capsule to the cell surface occurs through periplasmic scaffolds. These scaffolds
are areas where the cell plasma membrane and the outer membrane are in proximity
forming structures called Bayer junctions (182). The ABC transporter, KpsM and KpsT,
form a functional transporter dimer that binds directly to the polysaccharide and exports
it through an export channel. KpsD, which is a transporter protein in the periplasmic
space, could be involved in joining the membranes closely to facilitate the export to the
outer membrane (8).
The regulation of CPS expression in C. jejuni is not fully understood. There is no
experimental evidence of transcriptional regulatory patterns in CPS gene cluster.
However, some findings suggest that some genes are regulated differently depending on
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the growth conditions. High iron growth conditions are found to up-regulate the
expression of four genes in region 2 in C. jejuni NCTC 11168 (134). Furthermore, downregulation of three biosynthesis genes and four transport genes was reported after serial
passage of C. jejuni NCTC 11168 or 81-176 with HCT-8 human intestinal cells (37).
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Figure 2: Schematic representation of CPS cluster regions. E. coli group II and III
CPS regions compared to C. jejuni NCTC 11168 CPS cluster.
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Figure 3: Schematic representation of region 2 of both C. jejuni NCTC 11168 and
81-176 strains. The genes involved in GDP-manno-heptose synthesis and modification,
as well as the phosphoramidate synthesis and transfer genes.
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1.4.7.3.

Biological role in virulence:

CPSs are an essential part of the bacterial cell as they are involved in many
different functions. They provide protection from environmental conditions and host
defenses. Most importantly, they play an important role in bacterial pathogenesis and
virulence (170). The involvement of the capsule in C. jejuni virulence is strain dependant.
Multiple studies conducted on different strains of a capsule less mutant (KpsM)
revealed different results. In C. jejuni 81-176 strain, the KpsM mutant showed inability to
colonize or to invade cells. In a ferret model, as well as in intestinal cells, the KpsM
mutant of C. jejuni 81-176 strain exhibits decreased invasion levels (18, 109). However
in NCTC 11186 strain, although the KpsM mutants showed a significant reduction in the
colonization of chicken intestine, it was more adhesive and invasive to the epithelial cells
in vitro than the wild type (78, 184).
CPS also protects C. jejuni from the innate immune system mediators, such as
serum complements, and cationic antimicrobial peptides (109). Indeed, KpsM mutant in
NCTC 11186 strain showed high susceptibility to serum, bile salt and phagocytosis (184).
It is also believed that the extensive structural variation of CPS within C. jejuni strains
protects the bacteria from bacteriophages and helps in evading the host immune response
(71, 84). However, the complete mechanisms of these phase variable modifications in
virulence still unknown.
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1.5.

GDP-manno-heptose synthesis:

Heptose sugar is a natural component of the LOS and LPS of most Gram-negative
bacteria. They are producing ADP-L-glycero-D-manno-heptose as a component of the
core oligosaccharide by a single synthesis pathway (88, 95, 175). Interestingly, some
strains of C. jejuni possess additional heptose biosynthesis pathway to produce GDP-Dglycero-α-D-manno-heptose (GDP-manno-heptose). An identical pathway was identified
in Aneurinibacillus thermoaerophilus and the enzymes have been used for an in vitro
synthesis of GDP-manno-heptose for biochemical analyses (31, 87) (Figure 4). The genes
involved in the synthesis of GDP-manno-heptose in C. jejuni are encoded in region 2 of
the capsular cluster (Figure 3). The synthesis pathway starts by the conversion of Dsedoheptulose-7-phosphate (sedoheptulose-7P) into D-glycero-α-D-manno-heptose-7phosphate (heptose-7P) by the phosphosugar isomerases GmhA. The kinase HddA then
adds a phosphate group to generate D-glycero-α-D-manno-heptose-1,7-biphosphate
(heptose-1,7P). One phosphate is removed by GmhB giving D-glycero-α-D-mannoheptose-1-phosphate. Lastly, HddC acts to add a guanine nucleotide from a Guanine
triphosphate molecule (GTP) to generate the activated end product GDP-D-glycero-α-Dmanno-heptose (82, 175). In some C. jejuni strains, this heptose is further modified
before integration into the CPS.
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Figure 4: Synthesis of GDP-D-glycero-D-manno-heptose. The biosynthesis enzymes
of GDP-D-glycero-D-manno-heptose in C. jejuni are in bold to the left of the reaction
arrows, and the synthesis enzymes in Aneurinibacillus thermoaerophilus are to the right
side of the arrows.
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1.6.

C. jejuni GDP-manno-heptose modification:

Unique configurations of heptose are expressed in the CPS of different pathogenic
bacteria, in C. coli, and in Burkholderia pseudomallei (9, 10, 144, 160). They are also
found in molecules other than the CPS such as in the exopolysaccharide of C. lari and the
lipopolysaccharide of Yersinia pseudotuberculosis (13, 151). These modified heptoses
are important for bacterial virulence and could be involved in bacteria-host interaction.
In C. jejuni 81-176 and NCTC 11168 strains, two modified heptoses were
identified, 6-deoxy-D-altro-heptose and 3,6-OMe-L-gluco-heptose, respectively (9, 160).
The genes involved in the synthesis of the modified heptoses, as well as their synthesis
pathways, have been characterized (110-112).
1.6.1. The modified heptose role in virulence:

Complex carbohydrates are usually found on the bacterial cell surface and they
are involved in virulence or immune evasion. They are essential components of the CPS
and LOS in pathogenic bacteria. Enzymes involved in the biosynthesis and modification
of these sugars have gained much attention as antibacterial targets due to their
involvement in virulence. For example, a well-studied C3/C5 epimerase (RmlC) and
other homologous enzymes, in E. coli, Pseudomonas aeruginosa, Streptococcus mutants,
and Mycobacterium tuberculosis, are involved in the dTDP-L-rhamnose synthesis
pathway (143, 163). Deletion of one of the genes involved in this pathway resulted in a
significant decrease in virulence (143, 173). Likewise, a C3/C5 Epimerase/C4 reductase
(GFS) is involved in the GDP-L-fucose synthesis pathway. L-fucose is essential for
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virulence and host mimicry of some pathogenic bacteria, such as E. coli and H. pylori
(124, 157).
All these examples are for hexose derivatives made by hexose-modifying
enzymes. The enzymes that are involved in the synthesis of heptose derivatives are also
found to play a key role in the virulence of many pathogens, such as Yersinia
pseudotuberculosis, E. coli, and C. jejuni (70, 175, 184). In Y. pseudotuberculosis,
disrupting the synthesis of these modified heptoses has been shown to decrease virulence.
Mutants lacking the 6-deoxyheptose in the LPS are less motile and more sensitive to
antimicrobial peptides (70). Recently, the involvement of the modified heptoses in the
virulence of C. jejuni NCTC 11168 has been elucidated in vitro by testing four heptose
biosynthesis mutants, wcaG::cat, mlghB::cat, mlghC::cat, and wcaG∆::cat (Figure 5)
(184). In the serum and bile salt killing assay, all mutants were more susceptible to
killing than the wild type, with different survival ratio for each. In the epithelial cells
adhesion and invasion assay, mlghB::cat and mlghC::cat were not invasive to epithelial
cells (130, 184). In addition, all mutants showed less colonization in the chicken intestine
compared to the wild-type with variation between the mutants (184). All these data
indicate the role that the modified heptoses have with respect to bacterial colonization,
invasion of host cells, and response to host defense.
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Figure 5: Schematic representation of region 2 of C. jejuni NCTC 11168 heptose
biosynthesis mutants and the capsule-less mutant. From top to bottom, showing the
deletion positions in each of wcaG::cat, mlghC::cat, mlghB::cat, wcaGΔ::cat, and
kpsM::kan strains (184).
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1.6.2. The modified heptose synthesis enzymes:

Several nucleotides modifying enzymes are encoded in region 2 of C. jejuni 81176 and NCTC 11168 CPS cluster. The 6-deoxy-D-altro-heptose synthesis enzymes in C.
jejuni 81-176 are DdahA, DdahB, and DdahC, a C4/C6-dehydratase, C3-epimerase, and a
C4 reductase, respectively. A post-transcriptional regulatory enzyme, WcaG, is a C4
reductase. On the other hand, the enzymes involved in the 3,6-OMe-L-gluco-heptose
synthesis in C. jejuni NCTC 11168 strain are MlghB and MlghC, encode a C3/C5
epimerase and C4 reductase, respectively. A homologue to WcaG has also been identified
(110-112). In addition, two methyltransferases were identified. The O6 methyltransferase
is Cj1426, and it was renamed MlghD following the alphabetical order of the synthesis
enzymes in the pathway. Preliminary data from Creuzenet lab showed the O3
methyltransferase could be Cj1419, renamed as MlghE (unpublished).

1.6.3. The modified heptose synthesis pathways:

The homologous epimerases, DdahB and MlghB, are 81% identical and 98%
similar in their protein sequence. While the homologous reductases, DdahC and MlghC,
are 57% identical and 90% similar. Despite this similarity, these enzymes perform a
strain-specific activity to generate strain-specific modified heptoses.
The synthesis pathway for GDP-6-deoxy-D-altro-heptose in C. jejuni 81-176 was
first established in our laboratory by the characterization of the first enzyme in the
pathway, DdahA, and the regulatory enzyme WcaG (110, 112). DdahA performs
sequential dehydration activity on C6 and C4 of the substrate GDP-manno-heptose to
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generate GDP-6-deoxy-4-keto-D-lyxo-heptose (P1). This product can be either reduced at
C4 by WcaG, with the co-factor NADPH, in a side-branch pathway to down-regulate the
end product formation, or epimerized in a linear pathway to produce the final product. In
the linear pathway, DdahB epimerizes P1 on C3 to produce GDP-6-deoxy-4-keto-Darabino-heptose. This product is then reduced at C4 by DdahC, with the co-factor
NADPH, to yield the final product GDP-6-deoxy-D-altro-heptose (Figure 6-A).
In NCTC 11168 strain, the 4-keto derivative of the GDP-manno-heptose is
predicted to be generated by C4 oxidation activity. This oxidation is necessary to
generate the substrate for the epimerase MlghB. However, no gene coding C4-oxidases
was identified in the heptose modifying genes area or anywhere in the genome. In vivo,
MlghB generates GDP-4-keto-L-xylo-heptose from the oxidized substrate. This product is
reduced at C4 by MlghC to give the final modified heptose GDP-L-gluco-heptose that is
O-methylated at O6 and O3 by MlghD and MlghE, respectively (Figure 6-B). However,
the location of the methylation events in the pathway is still under investigation.
Because the potential GDP-manno-heptose oxidase has not been identified,
MlghB’s substrate is not available for biochemical studies. The GDP-6-deoxy-4-keto-Dlyxo-heptose (P1) generated by DdahA was used as a surrogate substrate for MlghB in an
experimental pathway (Figure 7). MlghB performs C3, C5, or both epimerizing activity
on P1 to generate three products in equilibrium, GDP-6-deoxy-4-keto-L-arabino-heptose
(P4α), GDP-6-deoxy-4-keto-L-ribo-heptose (P4β), and GDP-6-deoxy-4-keto-L-xyloheptose (P4γ). An interconversion between P1 and the three epimerized products was
observed. Finally, P4γ is reduced by MlghC at C4 to produce the final modified heptose
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GDP-6-deoxy- L-gluco-heptose (P5γ). The C3 epimerized product (P4α) generated by
MlghB from the surrogate substrate was identical to the DdahB product. This observation
was supported by the fact that the DdahC can also use P4α obtained by MlghB to
generate GDP-6-deoxy-D-altro-heptose (P5α).
The existence of strain-specific features of these enzymes suggests the importance
of understanding the molecular structure and the mechanism of performing such specific
activity. No structure for these enzymes or for homologous GDP-manno-heptose
modifying enzymes was available at the onset of our studies.
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Figure 6: Comparative GDP-6-deoxy-D-altro-heptose and GDP-3,6-O-Me-L-glucoheptose in vivo synthesis pathways of C. jejuni. A. The established synthesis pathway
of GDP-6-deoxy-D-altro-heptose in 81-176 strain. B. The investigated synthesis pathway
of GDP-3,6-O-Me-L-gluco-heptose in NCTC 11168 strain. MlghA is an oxidase
(unknown). MlghD and MlghE are the methyl transferase that introduces methyl group to
O6 and O3, respectively in yet unidentified locations along the pathway. Possible
methylation sites are denoted by a question mark. Reproduced figure from (McCallum,
2013) (111).

Figure 7: Experimental pathway for GDP-6-deoxy-D-altro-heptose and GDP-6deoxy- L-gluco-heptose synthesis in vitro. MlghB generates P4α, P4β and P4γ from the
surrogate substrate P1 that is formed by dehydration of GDP-manno-heptose by DdahA.
MlghC reduces P4γ to form the final product GDP-6-deoxy- L-gluco-heptose. While
DdahC reduces P4α to give for GDP-6-deoxy-D-altro-heptose. Reproduced figure from
(McCallum, 2013) (111).
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1.7.

Enzymes structure:
To study the configuration of an enzyme binding site, it is crucial to solve the

three-dimensional structure. The 3D structure will provide essential biological and
biochemical data that cannot be provided by a linear amino acid sequence. The tertiary
structure can be obtained by a well-established experimental methods such as X-ray
crystallography and nuclear magnetic resonance (NMR) (97). There are also
computational methods dedicated to determine the structure in silico, known as protein
structure modeling.
1.7.1. Homology modeling:

Homology modeling, also known as template-based modeling (TBM), refers to
the prediction of the 3D structure of a protein based on its homology with a protein of
experimentally determined structure (186). Four decades have been spent on establishing
and developing ways to solve proteins structures by computational scientists (108).
Homology modeling is an important and feasible method to solve the structure of
proteins that cannot be solved experimentally due to the limitations and the difficulties of
the experimental approaches (1, 108, 186).
There are four main steps for homology modeling (96, 186). The primary
sequence of the protein is needed first to identify homologous proteins through the
protein data bank (PDB). Second, the sequence is aligned to the template sequence using
one of the different reliable alignment softwares. Sequence alignment is the most
important step in homology modeling, and any error in this step is irreversible (186).
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Based on the alignment between the protein and the template, the model building can be
achieved by the generation of the backbone and modeling the structural loops and sidechains (96). Then comes to the last step, which is the model refinement and optimization.
In this step, the side-chains are tuned by predicting the side-chain rotamers with high
accuracy based on different parameters (96, 186)
There are many software that are widely used for model building available for
public, such as NEST, COMPOSER, SWISS-MODEL, and MODELLER (186). SWISSMODEL is a web-based workspace that uses a structure template database derived from
the Protein Data Bank (7). The closest homology of the template to the target is identified
using BLAST query. The templates with the highest quality are selected for model
building (7). Model quality estimation is done using the Qualitative Model Energy
Analysis (QMEAN) scoring system. It is a scoring system that describes the major
geometrical conditions of protein structures (20).
1.7.2. X-ray crystallography:

X-ray crystallography is one of the most advanced techniques to investigate the
molecular structure of a protein. X-rays are high-energy electromagnetic waves with a
very short wavelength. Crystallographers use x-rays that range from 0.5 to 1.5 angstrom
as rulers to measure the distance between atoms in a crystal (156). In crystalline solids,
the interatomic spacing is used as a diffraction gradient for x-rays with a wavelength of
approximately one angstrom.
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There are three main steps for protein crystallography analysis (117). Taking into
account the fact that each step has its limitation, the whole technique can be time
consuming and may not be successful with all proteins (1, 42). The first step is protein
crystallization. The principle of crystallization is to obtain the protein in a solid form out
of the solution in a fixed biological conformation. The protein crystals are grown by
precipitation and condensation (156). The second step is firing a beam of x-rays at the
tiny crystal of the studied protein. The crystal scatters the x-ray into specific diffraction
patterns that are photographed by an electronic detector. Different orientations of the
crystal are needed to capture in three dimensions different diffraction patterns of the xray. These patterns are used to mathematically solve the precise position and arrangement
of atoms in the crystal using Bragg’s law (75). The last step is data processing and
analysis (159). Although it is a mathematically complex procedure, there are wellestablished softwares to process the data (136, 159, 174). After several stages of analysis
and troubleshooting, comes the refinement to produce a three-dimensional digital image
of the protein.
1.8.

Enzymes active site:

Enzymes are one of the most studied biological molecules because they catalyze
numerous reactions in nature. The functional portion contains a combination of residues
side chains that form the catalytic unit (191). This unit is also known as the catalytic
toolkit. In this catalytic toolkit, the polar and charged amino acids are generally involved
directly in catalysis (63). Hydrophobic residues are also observed in the active site of the
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enzymes. Although the hydrophobic residues are not involved directly utilizing reactions,
they do have an important roles in some enzymes, such as providing a proper medium
environment in the active site (63). Catalytic residues are defined by Zvelebil. et. al as the
amino acids that are directly involved in the catalysis by acting as general acid-base,
electrophiles, or nucleophiles (191). They also can be involved in polarizing or stabilizing
transition state intermediates. Bartlett. et. al added that residues that have an effect on
other residues or water molecules that are directly involved in catalysis should also be
classified as catalytic (19). Other group proposed that catalytic residues cloud have a
secondary interaction with other residues, which were classified as non-catalytic, to aid
the catalysis (63). This means that catalytic residues do not function independently. The
microenvironment provided by other residues in the active site is important for the
catalytic residues to function.
One of the catalytic residues that are most often found in enzymes active sites is
histidine. Histidine has a pKα close to neutral, which allows it to function as an acid-base
catalyst. It can also donate or accept hydrogen atom, stabilizes charged transition states,
and function as a nucleophile. Glutamate, aspartate, arginine and lysine are also
commonly found in active sites. These residues can provide charges that exert an effect
on other residues or on the substrate. Serine, threonine, tyrosine, glutamine and
asparagine are found less often. These residues need to be activated by interacting with
other residues to function.
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1.9.

Rational and hypothesis:

The existence of modified bacterial surface carbohydrates and their involvement
in bacterial virulence urge to further investigate their contribution to the pathogenesis in
details. The identification of these modified carbohydrate synthesis genes shed light on
important sugar-nucleotide modifying enzymes including dehydratases, epimerases and
reductases. Several studies showed that deletion of one of the sugar-nucleotide
modifying enzymes encoding genes results in interruption of the pathway and
consequently reduces the virulence of the organism (70, 143, 173, 175, 184) . These
findings suggest that theses enzymes could be potential antimicrobial targets. In fact,
successful attempts were made to design inhibitors for different enzymes, such as RmlC
in M. tuberculosis, and the first two enzymes in the GDP-manno-heptose synthesis
pathway (16, 47).
In C. jejuni, heptose epimerases and reductases were identified in two strains, 81167 and NCTC 11168. These enzymes are highly similar yet perform strain-specific
activities to generate different modified heptoses. They possess an interesting substrate
and products specificity, which warrants an investigation of their binding sites. However,
no structure of these enzymes or of homologous GDP-manno-heptose modifying
enzymes is available. Therefore, we hypothesized that the heptose modifying enzymes
in C. jejuni have specific catalytic residues that allow for substrate and product
specificity toward heptose-based substrate rather than hexose-based substrate.
These catalytic residues allow the enzymes to function differently on heptose despite
the high sequence and structure similarity.
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The role of the modified heptoses has been investigated with regards to bacterial
resistance to serum and bile salt, adhesion and invasion to host cells, as well as
colonization of the chicken reservoir of C. jejuni. However, their role in biofilm
formation, which is one of the virulence factors that allows bacterial persistence in
nature, still needs to be investigated. For this, we hypothesized that synthesis of the
modified heptoses is important for biofilm formation.
1.10. Objectives:

First, to investigate the structure and the active site of the epimerases (DdahB and
MlghB) and the reductases (DdahC and MlghC), enzymatic and structural approaches
were employed. All enzymes were structurally modeled on well-studied hexosemodifying enzymes homologues. The molecular structures of the enzymes were solved
by X-ray crystallography, done by a collaborator (Laura Woodward, under supervision of
Dr. James Naismith, St, Andrews University, UK). The starting substrate, GDP-mannoheptose, was synthesized in the lab for structural and enzymatic analysis. We also applied
site-directed mutagenesis to test specifically targeted residues for their involvement in
catalysis or substrate specificity. The enzymatic activity, product formation, and kinetics
were analyzed by capillary electrophoresis.
Second, to study biofilm formation, an in vitro biofilm formation experiment was
performed on the wild type C. jejuni NCTC11168 and on five capsular and heptose
biosynthesis mutants, kpsM, mlghB::cat, mlghC::cat, wcaG::cat, and wcaGΔ::cat.
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CHAPTER 2 – MATERIAL AND METHODS
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2.1.

Bacterial growth and culture conditions:

Escherichia coli strains, DH5α, ER2566, and BL21(DE3)pLysS were routinely
grown from -80C freezer stocks at 37°C on Luria Broth (LB) media (Bioshop, Canada).
They were grown either on agar plates or in broth shaking at 200 rpm. Antibiotic
supplements were added based on specific selection used at final concentration of 100
μg/ml ampicillin (Biobasic, Markham, Canada), 100 μg/ml carbenicillin, 30 μg/ml
kanamycin (Biobasic, Markham, Canada), and 34 μg/ml chloramphenicol (Fisher
Scientific, Canada). C. jejuni ATCC 700819 ( NCTC 11168), wild type and mutant
strains, were grown initially from -80C freezer stocks overnight on Tryptic Soy Agar
(TSA; BD, Canada). The media was supplemented with 10 μg/ml vancomycin (Biobasic,
Markham, Canada), 5 μg/ml trimethoprim (Sigma-Aldrich, Canada), and 5% sheep blood
(Cedarlane, Burlington, Canada). Either 15 μg/ml chloramphenicol or 90 μg/ml
kanamycin was added for selection of the mutants. C. jejuni cells were grown in a
microaerobic incubator (Nuaire) at 37°C in 5% oxygen, 10% carbon dioxide, 85%
nitrogen, and 90% humidity. Cells were then transferred onto another TSA plate and
grown for 24 hours. To grow C. jejuni in liquid media, Tryptic Soy Broth (TSA; BD,
Canada) was used. Media was supplemented with vancomycin, trimethoprim, 0.05%
pyruvate (Alfa Aesar, USA), and 5% horse serum (Invitrogen, Canada) and grown
shaking at 90 rpm.
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2.2.

Calcium chloride competent E. coli preparations:

To prepare competent E. coli DH5α, ER2566, and BL21 (DE3) pLysS, 3 ml
overnight culture was used to inoculate 100 ml of LB and incubated to reach an OD600 of
0.6. The cells were centrifuged at 5000 g (Eppendorf 5415D) for 10 minutes at 4°C. The
pellet was resuspended in 20 ml of cold 50 mM calcium chloride solution and incubated
on ice for 30 minutes then centrifuged as above. The pellet was resuspended in 5 ml of 50
mM calcium chloride and 5 ml of 50% glycerol, aliquoted to 200 µl and stored at -80C.
2.3.

Transformation into competent E. coli:

A volume of 100 µl of the competent cells was incubated on ice after adding 10 µl
of the transforming DNA for 30 min. Cells were then incubated at 42C for two min for
heat shock then immediately placed on ice for 10 min. After that, 600 µl of LB was added
to the cells, and they were incubated shaking at 37C for 90 min. Cells were then plated
on LB plates with antibiotic as specified for selection and incubated overnight.
Transformed colonies were patched the next day on a new plate and re-incubated for 6
hours. Every cell patch was used to inoculate 3 ml LB to grow overnight. Next day,
aliquots with 25% glycerol were made and stored at -80C.
2.4.

Plasmid extraction and agarose gel electrophoresis:

Plasmids were extracted from 3 ml LB overnight cultures of the transformed
DH5α. Cells were centrifuged at 5000 g. The pellet was resuspended in 100 µl of
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solution I (50 mM glucose, 25 mM Tris-HCl pH 8, 10 mM ethylenediaminetetraacetate
(EDTA, pH 8). Then 200 μL of Solution II (1% SDS, 0.2 M NaOH), and 350 μL of
Solution III (3M sodium acetate) were added with gentle mixing of the sample. After 10
minutes centrifugation at 4000 g, the supernatant was treated with the same volume of
cold isopropanol and mixed by ten times inversion and incubated at room temperature for
10 minutes. Samples were centrifuged as above, the pellet washed with 1 ml of cold 70%
and 100% ethanol. The pellet was left to dry at 37°C and finally resuspended in 50 μl of
sterile water. DNA samples were analyzed by agarose gel electrophoresis using TAE
buffer (40 mM Tris-acetate pH 8.3, 1 mM EDTA), 0.7% of agarose gel with 0.01%
ethidium bromide. Samples in 2 DNA loading buffer (Invitrogen) as well as 1 Kb DNA
ladder standard (Genedirex) were loaded on the gel and separated at 100 V. UV light was
used to visualize DNA bands.
2.5.

GDP-manno-heptose synthesis:

GDP-manno-heptose synthesis from sedoheptulose 7-phosphate (Carbosynth) was
performed using GmhA/B/C/D enzymes following previously established conditions
(31). Gmh enzymes were cloned previously from Aneurinibacillus thermoaerophilus into
pDEST-17 with a histidine tag, for GmhA, GmhB, and GmhC, and into pDEST-15 with a
GST tag for GmhD (31). After expression and purification (see section 2.12 for details)
small scale reactions were prepared to test sequential conversion of sedoheptulose 7phosphate by each enzyme. A master mix of 120 µl containing 0.5 mM sedoheptulose 7phosphate, 200 mM ammonium bicarbonate buffer pH 9.0, 0.52 mM ATP (Sigma) and
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2.5 mM MgCl2 was equally divided into five reaction tubes. The first reaction has no
enzyme added as a negative control. The other reactions had 0.2 µmol of either GmhA
only, GmhA and GmhB, GmhA, B, and C, or all enzymes, also contained GTP (Roche)
in a total volume of 50 µl. All reactions were incubated at 37C for 12 hours, centrifuged
at 5000 g for 30 minutes. The supernatant was passed through a 10 kDa cut-off
centricon and lyophilized. The lyophilized pellet was finally resuspended in 25 µl MilliQ
water for further analysis.
A large scale reaction of 15 ml was prepared in two steps. In the first step, the
reaction contained 2.6 mM sedoheptulose 7-phosphate, 400 mM ammonium bicarbonate
buffer pH 9.0, 10 mM MgCl2, 2.7 mM ATP, 1.0 µmol of GmhA, GmhB, and GmhC. The
reaction was incubated at 37C for 12 hours. After incubation, it was centrifuged and
passed through a 10 kDa cut-off centricon. The flow through was used for the second step
of the reaction to generate GDP-manno-heptose by the addition of 1.0 µmol of GmhD
and 1.9 mM GTP. After 12 hours incubation at 37C, the reaction was centrifuged and
passed through the centricon. The final conversion into GDP-manno-heptose was
monitored by the capillary electrophoresis.
2.6.

High-performance liquid chromatography analysis (HPLC):

To analyze various sugar products, anionic exchange HPLC with pulsed
amperometric detection (PAD) was used on a Dionex ICS 3000 instrument. CarboPac
PA1 column (4 250 mm; Dionex) was used after it had equilibrated with 100 mM
NaOH for 10 minutes. The samples from the small scale synthesis of GDP-manno-
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heptose were lyophilized and resuspended in deionized water (MilliQ-water) and 10 µl
was injected to the column. A linear gradient from 100- 500 mM of 1M NaOAc in 100

mM NaOH was applied for 40 minutes at 1 ml/min as reported previously (31).
2.7.

GDP-manno-heptose purification:
GDP-manno-heptose was purified using anion-exchange chromatography using a

High Q Econopac 5 ml column (Bio-Rad) as reported previously (31). A linear gradient
from 50 mM -1 M triethylammonium bicarbonate (TEAB) pH 8.5, was applied for 20
column volumes at 1 ml/min. Detection of sugar nucleotide was by UV light (260 and
214 nm). Desired fractions containing the suspected GDP-manno-heptose were pooled
and lyophilized twice with resuspension in water between both lyophilization steps.
Finally, they were resuspended in water and analyzed by CE along with previously
characterized GDP-manno-heptose for product identification and purity assessment.
Quantitation of GDP-manno-heptose was performed using a Nanodrop
spectrophotometer using εGTP = 12000 mol-1 L cm-1.
2.8.

Comparative functional analysis:

A comparative functional analysis between the heptose modifying enzymes and
well-studied homologous enzymes with known structure was done. The function of
residues in the binding site was predicted based on structural sequence alignment to
residues of known function in the homologues. The epimerases were compared to a
dTDP-hexoluse C3/C5 epimerase (RmlC) from Salmonella enterica and Streptococcus
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suis (45, 55). The reductases were compared to the GDP-fucose synthetase (GFS), a
GDP-4-keto-6-deoxy-D-mannose C3/C5 epimerase and C4 reductase from E. coli (55).
2.9.

Structural modeling:

Homology modeling approach was used to model the structure of the epimerases,
DdahB and MlghB, and the reductases, DdahC and MlghC. SWISS-MODEL workspace
(http://swissmodel.expasy.org/) was used to build the structure model for the wild type
and mutant enzymes (7). In the main page of SWISS-MODEL workspace, the protein
sequence of the wild type or the mutant was entered in the target sequence field. The
protein name was written in the project title field then the option of searching for a
template was chosen. The software then showed a list of templates ordered from the
highest identity to the target sequence to the lowest identity. On the top of the list, several
tabs allow the user to check the selected templates before model building. The sequence
similarity tab shows how similar the selected template is to the target protein. The
alignment tab shows the protein sequence of the target aligned with the template
sequence. The user can select more than one template for model building. After template
selection, model building was started by clicking on build models button. In a new
window, all build models are shown. The best model was chosen based on the QMEAN
score and exported from SWISS-MODEL as protein data bank files (PDB) (20). The 3D
structures were then visualized and analyzed using PyMol software
(https://www.pymol.org/).
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2.10. Subcloning and crystallography:

The epimerase genes ddahB and mlghB were subcloned into a pEHISTEV vector
for crystallography purposes. The pEHISTEV plasmid was received from Dr. Naismith
(St Andrews, UK) and transformed into DH5α with kanamycin selection (103). After
plasmid extraction and purification, cohesive ends were generated by restriction digest
using 1.0 U of BamHI and NcoI restriction enzymes (BioLabs) and 1REact 3 buffer
(Invitrogen). Both ddahB and mlghB genes were PCR amplified from pET-ddahB and
pET-mlghB plasmids by iMax DNA polymerase (iNtRON) and the primers listed in
Appendix 1 (112). PCR products were then analyzed by agarose gel electrophoresis and
purified using PCR purification kit following manufacturer’s instructions (Geneaid). PCR
products were then subjected to restriction cut using AflIII (Invitrogen) and BamHI for
ddahB, NcoI and BamHI for MlghB in 1REact 3 buffer. To insert the cut PCR product
into the pEHISTEV vector, reactions containing each insert, the vector, 26 U ligase
(BioLabs), and 1 ligation buffer were incubated at room temperature overnight. After
analyzing the products by gel electrophoresis, they were transformed into DH5α.
Extracted plasmids from recovered clones were sequenced for confirmation using T7
promoter primer (Roberts Research Institute sequencing facility, London, Ontario).
The crystallography was done by collaborators, Dr. James Naismith and a PhD.
candidate, Laura Woodward in St. Andrews’ University, UK. The molecular structure of
both epimerases DdahB and MlghB were solved by molecular replacement on the crystal
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structure of RmlC. The structure of MlghB/GDP-mannose was solved by cocrystallization with GDP-mannose as an analog substrate.
2.11. Site-directed mutagenesis:

Site-directed mutagenesis was performed following the QuikChange®
mutagenesis procedure using iMax DNA polymerase. To generate the mutants, reactions
containing 10 pmol of either the forward or the reverse primer (Appendix 2), 20 ng of the
template plasmid, and 0.05 U of iMax polymerase in 1 iMax buffer were set up. The
PCR was programmed to 30 cycles of denaturation at 98°C for 30 seconds followed by
annealing at each primer annealing temperature, and extension at 72° based on the iMax
polymerases speed, 1kb/min. After ten PCR cycles, individual reactions containing either
the forward or the reverse primer were combined, 0.05 U of iMax enzyme was added,
and PCR was resumed for 20 more cycles and final extension at 72°C for 7 minutes. The
PCR product was then treated with DpnI (Stratagene) for one hour and transformed into
E. coli DH5α as explained above. Purified plasmids were sequenced with T7 promoter
primer for confirmation (Roberts Research Institute sequencing facility, London,
Ontario).
2.12. Protein expression and purification:

The modified heptose synthesis genes, mlghB and mlghC, from C. jejuni
NCTC11168, and ddahA, ddahB, ddahC from C. jejuni 81-176, were previously cloned
into pET vector with N-terminus 6 histidine tags (110, 112). The GDP-mannose
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dehydratase, hp0044 gene, was previously cloned from Helicobacter pylori into pGEX2T with N-terminus GST-tag (31). Genes for GDP-manno-heptose synthesis were cloned
from Aneurinibacillus thermoaerophilus (87). The gmhA, gmhB, and gmhC genes were
previously cloned into pDEST17 with N-terminus 6 histidine tag, while gmhD was
cloned into pDEST15 with N-terminus GST tag (31). Expression of all proteins was
carried using E. coli ER2566, BL21 (DE3) pLysS, or DH5α expression strains (see Table
1 for specifics). Cells were grown in LB with shaking at 37C to OD600 of 0.6. To induce
expression 0.1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) was added. For the
modified heptose synthesis enzymes, 300 ml cultures were induced for three hours at
37C for MlghB, MlghC, DdahA, DdahC, and at 25C for DdahB. The GDP-mannose
dehydratase, HP0044, was induced from DH5α at 37C for three hours. For GDP-mannoheptose synthesis enzymes, 1 L cultures were induced at 25C for three hours for GmhA,
GmhB, GmhC, and 16 hours for GmhD.
Purification of all proteins was done using affinity chromatography purification
using FPLC. For N-terminally histidine-tagged proteins, the expressed cell pellets were
resuspended in binding buffer (0.1 M NaCl, 20 mM imidazole, 20 mM Tris-HCl) with a
pH away from the protein isoelectric point (Table 1). After cell disruption under 25 psi
and ultracentrifugation, the proteins were purified by nickel chelation using a 1.6 ml of
Poros MC 20 column (4.6 100 mm; Applied Biosystems). After washing the nonspecific binding proteins, His-tagged proteins were eluted using a gradient of imidazole
concentrations. The GST-tagged GmhD and HP0044 were resuspended in PBS binding
buffer (140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, and 1.8 mM KH2PO4. pH 8.0).
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They were purified using 1 ml GSTrap FF column (GE Healthcare). Unbound proteins
were washed with binding buffer. Bound proteins were eluted using 0.01 M reduced
glutathione (Sigma). Pure protein fractions were preserved in 25% glycerol at -20 C.
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Table 1: Expression and purification conditions:

Strain

Gene

Vector

Tag

Mass
(kDa)*

Purificat
ion pH

E. coli expression
strain

C. jejuni
NCTC
11168

mlghB

pET

His

22.2

8.0

BL21 (DE3) pLysS

mlghC

pET

His

41.7

7.0

ER2566

ddahA

pET

His

40.5

8.0

BL21 (DE3) pLysS

ddahB

pET

His

22.1

7.0

BL21 (DE3) pLysS

ddahC

pET

His

40.7

7.0

ER2566

hp0044

pGEX-2T

GST

73.9

8.0

DH5α

gmha

pDEST17

His

25.0

7.5

gmhb

pDEST17

His

39.1

7.5

gmhc

pDEST17

His

24.7

7.5

gmhD

pDEST15

GST

52.6

8.0

C. jejuni
81-176
H. pylori

A.
thermoae
rophilus

BL21 (DE3) pLysS

* Protein mass with the tag
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2.13. SDS-polyacrylamide gel electrophoresis of proteins:

SDS-PAGE analysis for proteins was performed using stacking gel (4 %
polyacrylamide (Bio-Rad, mini-gel system), 125 mM Tris pH 6.8, 0.1 % SDS, 0.5%
ammonium persulfate (APS), and 0.1 % tetramethylethylenediamine (TEMED)), and
separating gel (12% polyacrylamide, 375 mM Tris pH 8.8, 0.1 % SDS, 0.1 % APS, and
0.1 % TEMED). Before loading on the gel, protein samples were incubated for 10 min at
100C in SDS loading buffer (0.625 M Tris pH 6.8, 2% SDS, 2% β-mercaptoethanol,
10% glycerol, and 0.002% bromophenol blue). Gels were run in Tris-glycine running
buffer (25 mM Tris, 190 mM glycine, 1% w/v SDS. pH 8.3) at 10 mA through stacking
gel and 20 mA through the separating gel. Proteins were visualized by Coomassie blue
staining (10% acetic acid, 25% ethanol, 0.001% (w/v) Coomassie blue).
2.14. Western blotting:

Western blotting was performed after SDS-PAGE. Proteins were transferred from
the gel to a nitrocellulose membrane (Bio-Rad). The transfer was performed for 45
minutes in Tris-Glycine Transfer buffer (192 mM glycine, 25 mM Tris pH 8.3, 20%
methanol, 0.01% SDS) with a constant current of 180mA (Bio-Rad transblot system).
After transfer, the membrane was washed with water and stained with 0.1% Ponceau S
Red to visualize the transferred proteins. After scanning the membrane, the Ponceau stain
was washed by 1 PBS buffer (137 mM NaCl, 2.7 mM KC1, 8 mM Na2HPO4, and 1.46
mM KH2PO4, pH 7.2). The membrane was blocked with 5% skim milk in 1 PBS buffer
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overnight at 4C, or 2.5% for 30 minutes at room temperature. After blocking, the
membrane was washed twice in PBS-Tween-20 (PBS and 0.1% Tween-20) and once in
PBS buffer for 5 minutes each. Primary antibody (Sigma) was added to the membrane
and incubated for one hour. After washing twice in PBS-Tween-20 and once with PBS,
the secondary antibody (Sigma) was added and incubated 40 minutes in the dark. See
Appendix 3 for the list of antibodies used. Finally, the membrane was washed again as
above and the protein was visualized using Licor Infrared Imaging system at wavelengths
of 700nm or 800nm.
2.15. Bradford assay:

Total protein concentration was measured from pure protein fractions before
adding the 25% glycerol. The assay standard curve was made using serial dilutions of
bovine serum albumin (BSA). The procedure was performed according to the
manufacturer’s instructions (Bio-Rad). Absorbance was taken at 595 nm. All samples
were measured in triplicate.
2.16. The epimerases reactions and kinetics:
2.16.1. GDP-manno-heptose reactions:

To test the activity for the epimerases, a master mix of 80 µl containing 0.17 mM
GDP-manno-heptose, 1.5 µmol DdahA, 200 mM Tris pH 7.5, and 0.13 mM NADP+ that
was used as an internal standard to facilitate peak alignment on the capillary
electrophoresis (CE) electeropherograms. The master mix was incubated at 37C for 30
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minutes then frozen at -20C before further usage. The total conversion of GDP-mannoheptose into the desired substrate for the epimerases (P1) was confirmed by testing an
aliquot from the master mix using CE. The master mix was then divided into nine tubes,
8 µl each. To each tube, 1.0 pmol of either MlghB or DdahB, wild type or mutants were
added. All reaction tubes were incubated at 37C for 30 minutes. At the end of the
incubation, they were frozen at -20C.
The kinetics were performed with the same substrate and enzymes concentrations
in master mixes as mentioned above. The reactions were incubated for 5, 10, 15, 20, 30,
and 45 minutes. At each time point, the reactions were snap frozen in dry ice/ ethanol
mixture and individually analyzed by CE.
2.16.2. GDP-mannose reactions:

For the epimerases, a master mix of 80 µl containing 0.77mM GDP-mannose, 2.0
pmol HP0044, 200 mM Tris pH 7.5, and 0.1 mM NADP+ was incubated at 37C for 90
minutes. After the total conversion of GDP-mannose into P1’ was confirmed by CE, the
mix was frozen at -20C then divided into nine tubes, 8 µl each. For each tube 5 pmol/ul
of DdahB or 1 pmol/ul of MlghB, wild type or mutants was added. Reaction tubes were
incubated one hour for MlghB and 5 hours for DdahB at 37C.
The kinetics were performed only for MlghB with the same substrate and
enzymes concentrations in master mixes as mentioned above. The reactions were
incubated for 20, 30, 60, 150, 240, and 300 minutes. At each time point, the reactions
were snap frozen in dry ice/ ethanol mixture and individually analyzed by CE
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2.17. The reductases reactions and kinetics:
2.17.1. GDP-manno-heptose reactions:

To test the activity of the reductases, a master mix of 56 µl containing 0.17 mM
GDP-manno-heptose, 1.5 µmol DdahA, 2 pmol MlghB, 200 mM Tris pH 7.5, and 0.5
mM NADPH as a co-factor for the reductases. The master mix was incubated at 37C for
30 minutes then frozen at -20C. An aliquot tested by CE for the generation of the
epimerized sugar nucleotide by MlghB, P4α, P4β, and P4γ. The master mix was then
divided into six tubes, 8.0 µl each, and 1.0 pmol of either MlghC or DdahC, wild type or
mutants was added. Reactions were incubated at 37C for 30 minutes then frozen -20C.
To test the substrate specificity of the reductases, wild type and mutants, a base
reaction containing 0.17 mM GDP-manno-heptose, 1.5 µmol DdahA, 2 pmol MlghB, 200
mM Tris pH 7.5, and 0.5 mM NADPH as a co-factor for the reductases. The master mix
was incubated at 37C for 30 minutes then frozen at -20C. An aliquot tested by CE for
the generation of the epimerized sugar nucleotide by MlghB, P4α, P4β, and P4γ. The
master mix was then ultrafiltered to remove MlghB from the reaction using a 10 kDa
cutoff centricone. The filtrate was eluquted and 1.0 pmol of either MlghC or DdahC, wild
type or mutants was added. Reactions were incubated at 37C for 30 minutes then frozen
-20C then analyzed by CE. The same method was used to perform the kinetics of the
reductases. The same concentrations of the substrate and the enzymes were used to
incubate the reductases, wild type and mutants for 7 time points, 5, 10, 15, 20, 30, 45, and
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60 minutes at 37C. All reactions were snap frozen in dry ice/ ethanol mixture at each
time point and individually analyzed by the CE.
2.17.2. GDP-mannose reactions:
The activity of the reductases was tested on different GDP-mannose substrates in
two different reaction sets. The activity of the wild type DdahC and MlghC were tested
on both P4’ and P1’, as well as on P1’ by itself. For the first set, a master mix of 30 µl
containing 1.25 mM GDP-mannose, 2.0 pmol HP0044, 2.0 pmol MlghB, 200 mM Tris
pH 7.5, and 0.5 mM NADP+ was incubated at 37C for 90 minutes. After the total
conversion of GDP-mannose into P1’, and formation of P4’ was confirmed by CE, the
reaction was divided where 1.0 pmol of DdahC or MlghC were added and incubated for
60 minutes at 37C then frozen -20C then analyzed by CE.
The second set was to test the activity on P1’ only. A base reaction containing
0.77 mM GDP-mannose, 2.0 pmol HP0044, 200 mM Tris pH 7.5, and 0.1 mM NADP+
was incubated at 37C for 90 minutes. After the total conversion of GDP-mannose into
P1’ was confirmed by CE, the mix was ultrafiltered to remove HP0044 from the reaction.
The filterate was divided and 1.0 pmol of eather DdahC or MlghC was added and
incubated for 60 minuts at 37C then frozen -20C then analyzed by CE.
To test the differences between the wild and the mutants of DdahC and MlghC, a
reaction containing 0.77 mM GDP-mannose, 2.0 pmol HP0044, 200 mM Tris pH 7.5,
and 0.5 mM NADP+ was incubated at 37C for 90 minutes and ultrafiltered after total
conversion of GDP-mannose into P1’.
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The kinetics were performed in a similar reaction to the first set mentioned above.
The reactions were incubated for 10, 20, 35, 50, 70, and 95 minutes at 37C. All reactions
were snap frozen in dry ice/ ethanol mixture at each time point and individually analyzed
by the CE.
2.18. Capillary electrophoresis analysis:

Capillary electrophoresis for sugar nucleotides analysis was performed on a
Beckman MDQ/ Gold instrument using the 32 Karat software and 57 cm bare silica
capillary. The sample running method includes initial washing of the capillary with 200
mM Borax buffer pH 9.0 for two minutes at 20 psi, followed by four seconds of sample
injection. The separation of the sample was done under 26 kV and detection was at 254
nm. After each sample, the capillary was washed for two minutes with water, two
minutes with 0.1M NaOH, and two minutes with water again. Using the 32Karat
software, product formation was estimated by integration of surface areas under the
substrate and product peaks.
2.19. Biofilm assay:
The wild-type strain, C. jejuni NCTC11168, was tested for biofilm formation
along with four heptose biosynthesis mutants and a capsule-less mutant that were
generated previously in our lab, wcaG::cat, mlghC::cat, mlghB::cat, and wcaGΔ::cat
(184). KpsM::kan that is known to be a capsule-less strain was used as a negative control.
All strains were grown as explained in section 2.1. In a 100mm diameter glass tube, one
ml of a cell suspension adjusted to OD600 of 0.7 was incubated under aerobic or
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microaerobic static conditions at 37°C for 3 days. Three replicates were prepared for each
strain. After the three days incubation, a set of tubes was taken out of the incubator every
day for four days, washed three times with water to remove planktonic cells, and left to
dry for 30 minutes. To stain biofilm, 1 ml of 1% crystal violet was added to each tube and
incubated at room temperature for one hour. Excess stain was washed with water three
times, and the tubes were left to dry for 30 minutes. Finally, the stained biofilms were
detached from the glass wall by adding 1 ml of 30 % acetic acid and incubating for an
hour. Two hundred µl of each sample were transferred to a 96-well microtiter plate to
measure the absorbance at 950 nm (146). Statistics were done using one-way ANOVA
test for two independent experiments.
2.20. Hitchcock and Brown method for CPS and LOS extraction:

The cell pellets from 1 ml of the same cell suspensions that were used for the
biofilm assay were washed and resuspended in lysis buffer (2% SDS, 4% 2mercaptoethanol, 10% glycerol, 1 M Tris pH 6.8), and bromophenol blue). After heating
the sample at 100C for 30 min, it was treated with 2.5 µg of proteinase K (Roche) at
60C for an hour (69). Finally, 15 µl of the sample were loaded on SDS gels with TrisGlycine buffer as explained bellow.
2.21. SDS-polyacrylamide gel electrophoresis for CPS:

SDS-PAGE analysis for CPS samples was performed using stacking gel (4 %
polyacrylamide, 125 mM Tris pH 6.8, 0.1 % SDS, 0.5% APS, and 0.1 % TEMED), and
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separating gel (14% polyacrylamide, 3 M Tris, 1 M HCl, and 0.3% SDS buffer, pH 8.4,
0.1% APS, and 0.1 % TEMED). CPS cell suspensions were treated according to
Hitchcock and Brown method or saline extraction as explained above then loaded. The
gel was run in Tris-glycine buffer at 20 mA. The CPS was finally visualized by silver
staining as explained below.
2.22. Silver staining:

Silver staining of the carbohydrate samples that were separated by SDS-PAGE
was done according to Fomsgaard et al protocol (51). The gels were incubated shaking in
oxidizing solution (0.7% periodic acid, 40% ethanol and 5% acetic acid in MilliQ water)
at room temperature for 20 minutes. They were then washed four times over 15 minutes
with MilliQ water. After washing, the gels were stained with staining solution (0.19%
(v/v) 10 N NaOH, 1.3% (v/v) ammonium hydroxide, 0.7% (w/v) silver nitrate) for 10
minutes, followed by five washes with MilliQ water. The gel was developed in 0.005%
(w/v) citric acid and 0.05% (v/v) formaldehyde (37%) until bands became visible.
Finally, they were washed with MilliQ water and scanned.

CHAPTER 3 - RESULTS
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3.1.

GDP-manno-heptose synthesis:

The synthesis of GDP-manno-heptose from sedoheptulose-7-phosphate was done
following previously optimized conditions using GmhA, GmhB, GmhC, and GmhD
enzymes (31). GmhA, GmhB, and GmhC are histidine-tagged proteins and were purified
using nickel affinity chromatography. GmhD is GST-tagged and was purified by GST
affinity chromatography (Figure 8-A).
The synthesis of GDP-manno-heptose was initially carried on a small scale to
monitor the activity of the purified biosynthesis enzymes, GmhA, GmhB, and GmhC.
Because the last enzyme in the pathway, GmhD, has a very short lifespan, it was not
tested in the small scale analysis. Based on the HPLC analysis, the conversions of 0.5
mM sedoheptulose-7-phosphate into heptose-7-phosphate by GmhA was successful, but
not complete (Figure 8-B). The reaction where both GmhA and GmhB along with ATP
were used showed complete conversion of the sedoheptulose-7-phosphate into heptose1,7-biphosphate. Adding all the three enzymes, GmhA, GmhB, and GmhC resulted in the
formation of the heptose-1-phosphate (Figure 8-B). In a large scale, 5.4 mM of the
sedoheptulose-7-phosphate was used to generate the heptose-1-phosphate using 5 μmol
of GmhA, GmhB and GmhC. The products formation was analyzed by HPLC using
sedoheptulose-7-phosphate as a standard. The products migration time was assessed
based on the previously established methods where the products were identified by mass
spectrometry analysis (31).
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Figure 8: Synthesis of GDP-manno-heptose in small scale. A. SDS-PAGE analysis
of the purified GDP-manno-heptose synthesis enzymes. From 1 to 4, showing GmhA
(25 kDa), GmhB (38 kDa), GmhC (25 kDa), and GmhD (52 kDa). The left panel
shows the Coomassie blue stain, while the right panel shows the anti-histidine
western blot, for GmhA, GmhB, and GmhC, as well as the anti-GST tag western blot
for GmhD. B. HPLC chromatograms of small scale sequential conversion of
sedoheptulose-7-phosphate into heptose-1-phosphate. GmhA converts
sedoheptulose-7-phosphate (S7) into heptose-7-phosphate (H7) (trace b). GmhB
converts H7 into heptose-1,7-biphosphate (H1,7) by adding phosphate group from
ATP molecule that was provided in the reaction (trace c). GmhC removes one
phosphate from H1,7 to generate heptose-1-phosphate (H1) (trace d). The sugar peaks
are labeled in red, and their chemical structures are represented.
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3.2.

Epimerases comparative functional analysis and structure:

3.2.1. Comparative functional analysis:
The analysis of the active site of DdahB, a C3 epimerase, and MlghB, a
C3/C5 epimerase, was based on the knowledge obtained from studied RmlC enzymes
(45, 46, 55). RmlC, a dTDP-6-deoxy-D-xylo-4-hexulose C3/C5 epimerase, is the third
enzyme in the dTDP-L-rhamnose synthesis pathway. RmlC substrate has a 4-keto
group that is important to initialize the epimerization. In St. suis’s RmlC, Asn127
recognize the O4-keto group and binds it through the amide group, which lowers the
pKa of the protons attached to C3 and C5 (4, 45). The epimerization at C3 and C5 is
obtained in two chemical steps, deprotonation from one face of the sugar ring
followed by reprotonation at the opposite face at C3 and C5 position (45, 46).
Deuterium incorporation analysis indicates that RmlC could perform sequential C5,
C3 epimerization where C5 epimerization is faster than C3 epimerization (46). The
C3/C5 epimerized product that is generated by RmlC could not be detected in a
chemical reaction or directly quantified by biochemical assays (60, 118, 163). The
activity of RmlC was rather confirmed by coupled assay with the downstream
reductase, RmlD, by measuring the conversion rate of NADPH upon formation of
dTDP-L-rhamnose (46, 60). The explanation of why the RmlC product has never
been isolated is that it can exist only as an enzyme-bound intermediate that can only
disassociate after reduction by RmlD, which could form a complex with RmlC (118).
The residues that are involved in RmlC activity, His63-Asp170 dyad, Tyr133,
and Lys73, were identified in S. enterica’s RmlC by structural and biochemical
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assays (46). These residues are highly conserved among studied RmlC enzymes in
other bacteria. The His63-Asp170 dyad is important for both C3 and C5
epimerization of the substrate. Based on deuterium incorporation and mutagenesis
coupled with enzymes assays, His63Ala is catalytically inactive. This, together with
its location in the binding site suggests that His63 acts as a base to deprotonate the
sugar from the lower face of the ring at C3 and C5 positions, as it has a flexible side
chain conformation (45). The proton abstraction results in the formation of an enolate
anion that could be stabilized by Lys73 (45, 46). At the opposite face of the sugar
ring, Tyr133 donates a proton at C5 position. Tyr133Phe had 1000 fold reduction in
activity and some deuterium incorporation only at C3 but not at C5. This indicates
that the hydroxyl group of the Tyr133 side chain is essential for C5 but not for C3
epimerization. A conserved water molecule found close to C3 could be compensating
for Tyr133 function in the Tyr133Phe mutant by donating a proton (46). On the other
hand, Lys73Ala had 100 fold reduction in activity and a small amount of deuterium
incorporation at C5 but not at C3, suggesting that Lys73 is essential for epimerization
at C3 (46).
Based on co-crystallography of S. enterica’s RmlC with dTDP-phenol, the
residues that are involved in the ribose nucleotide binding are Phe27, Tyr139, Asn50
and Phe20 (55). The thymidine ring is stacked between the aromatic residues Phe27
and Tyr139. Asn50 is also interacting with the thymidine ring, while Phe20 from B
monomer stacks against the ribose ring of the nucleotide. The residues that interact
with the sugar ring, Asn127, Phe129, and Tyr138, were identified in St. suis’s RmlC
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(45). The Asn127 residue is important for the 4-keto substrate recognition by binding
to O4, which predicted to lower the transition state energy of C3 and C5 protons,
while both Phe129 and Tyr138 make Van der Waals interactions with C6 and O6.
The last two residues, Phe129 and Tyr138, are conserved among RmlC enzymes as
aromatic residues and most commonly found as Phe/Phe pair, which means that they
could be involved in stacking interactions with the sugar (54).
Similar to RmlC, C. jejuni NCTC 11168 epimerase, MlghB, is able to perform
C3/C5 epimerization on a different substrate, GDP-6-deoxy-4-keto-D-lyxo-heptose.
However, MlghB can release the three epimerized products that were detected by
capillary electrophoresis and identified by mass spectrometry (111). On the other
hand, the epimerase in C. jejuni 81-176, DdahB, can only epimerize the GDP-6deoxy-4-keto-D-lyxo-heptose at C3 generating one product under same conditions as
MlghB (111, 112). Based on sequence alignment with St. suis’s and S. enterica’s
RmlC with, both DdahB and MlghB have the conserved catalytic His67-Asp173
dyad, Tyr134, and Lys74 residues (the numbers are for DdahB and MlghB protein
sequences) (Figure 9) (Table 2). Therefore, His67 is predicted to be catalytic for
epimerization at C3 and C5 of the heptose substrate. On the other hand, Tyr134 and
Lys74 could be essential for epimerization at C5 and/or C3. Similar to RmlC’s
nucleotide binding residues, Phe27, Tyr139, Asn50 and Phe20 both DdahB and
MlghB have the residues that could be important for the nucleotide binding, Ile31,
Tyr142, Lys54, and Phe24. Aligned with the residue Asn127 that bind the 4-keto
group of the sugar ring in RmlC, DdahB and MlghB have Asn121. Therefore, it could
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be involved in the recognition of the 4-keto group of the substrate. Replacing the
Phe129 and Tyr138 in S. enterica’s RmlC, which are usually found as Phe/Phe pair in
other RmlC enzymes, DdahB and MlghB have His123 and Tyr132. Both residues
could function for catalysis or for stacking reaction with the substrate (32, 54, 55). In
S. enterica’s RmlC, there is a second His120-Asp84 dyad with unknown function that
is not conserved among other RmlC (46, 55). Conversely, in DdahB and MlghB the
aspartic acid is substituted by Gln85 that is positioned in close location to interact
with Asn121 through the amide group by a hydrogen bond (21, 63). This interaction
could be important for catalysis (45, 46, 55). The residues Asn121, His67, Tyr134,
Tyr132, and Lys74 have been targeted for mutagenesis to test their predicted function
in catalysis.
3.2.2. Site-directed mutagenesis:
Five and six mutants were successfully generated for DdahB and MlghB
respectively using a pET construct that was cloned previously in the lab, some of
which were generated by other lab members as indicated in Table 3 (112). The table
shows the rational of each mutant and the substituted amino acid. Asn121 that was
predicted to recognize the substrate by binding to O4 was mutated into serine, which
has a shorter side chain, lacks the amide group but has conserved polarity. For the
His67, two mutants were generated. It was mutated into alanine, which has a nonfunctional side chain, or into asparagine to conserve the polarity (46). The Tyr134, as
well as Tyr132, were mutated into phenylalanine to conserve the aromatic structure
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and eliminate the hydroxyl function (46). Finally, Lys74 was mutated into alanine to
eliminate the function of the side chain (46).
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Table 2: Comparative functional analysis of the conserved residues in the
epimerases binding site:

RmlC
S. enterica

Function (46,
55)

DdahB
MlghB
C. jejuni

Predicted
function

H76

Catalytic. Acts
like a base for
epimerization at
C3 and C5

H63

Catalytic. Acts
like a base for
epimerization at
C3 and C5

H67

Catalytic for
epimerization at
C3 and C5

D180

His76-Asp dyad.
Increases basicity
of H76

D170

His63-Asp dyad.
Increases basicity
of H63

D173

Catalytic His67Asp dyad.

Y140

Catalytic. The
OH group is 3.7Å
from C3 and
3.5Å from C5.

Y133

Catalytic. Proton
donor for
epimerization at
C5 and not
essential at C3

Y134

Catalytic for
epimerization at
C3 and C5

K82

Catalytic.
Stabilizes the
negative charge
after
deprotonation

K73

Catalytic. For
epimerization at
C3

K74

Catalytic for
epimerization at
C3

RmlC
St. suis

Function (45)

F36
Y145

F27
Interact with
thymidine ring.

N63
H29
N127

F129
Y138

G94

Y139

I31
Interact with
thymidine ring.

N50
Stacks against
the ribose ring.
Binds O4
(substrate
recognition)
Makes VDW
interactions with
C6 and O6. not
conserved in all
RmlC

Unknown

Y142

Interact with
thymidine ring.

K57

F20

Stacks against
the ribose ring.

F24

Stacks against
the ribose ring.
Binds O4
(substrate
recognition)

H120

Unknown. Could
interact with O4

N121

F122

Unknown

H123

Interact with the
sugar ring

F131

Unknown

Y132

Catalytic

D84

His120-Asp
dyad. Unknown
function

Q85

Catalytic.
Possible
interaction with
N121 (63).

68

Figure 9: Protein sequence alignment of the epimerases. Alignment of both RmlC
enzymes from S. suis and S. enterica with C. jejuni epimerases DdahB and MlghB
sequences. The residues of interest are highlighted, and the numbering is for C. jejuni
epimerases.
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3.2.3. Structure modeling:
Since the experimental approaches could be unsuccessful and time consuming
to solve the structure of some proteins, the structural modeling was used because it is
a feasible approach to solve the molecular structure of DdhaB and MlghB.
The best template for DdahB and MlghB used for modeling from SWISSMODEL workspace was within the highest QMEAN scoring templates (20). They
were modeled on dTDP-6-deoxy-D-xylo-4-hexulose C3/C5 epimerase (RmlC) from
S. enterica (PDB code 1DZR) (55). The resolution of the template is 2.17 Å. The
overall structure of both DdahB and MlghB showed that they are dimeric and highly
similar (Figure 10-A). Based on the structural alignment with RmlC, the sugarnucleotide binding site is located in the accessible cavity between the β-sheets within
each monomer (Figure 10-B). The residues in the binding site that are predicted to
have a role in substrate binding or catalysis based on the comparative functional
analysis have been represented in the model (45, 55).
The fact that DdahB can only epimerize at C3 in the same conditions as
MlghB whereas MlghB can do either or both epimerization at C3/C5 suggests two
hypotheses. The first is that DdahB could be lacking the catalytic residues that
function for C5 epimerization. No significant difference between the conserved
catalytic residues in DdahB and MlghB active site based on structural alignment.
Furthermore, most of the non-conserved residues had small hydrophobic side chains.
In fact, it has been shown previously in our lab that under prolonged incubation
conditions and high concentration of DdahB, DdahB can perform limited C5
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epimerization generating small amounts of the C5 and C3/C5 epimers. This means
that it has the functional residues to perform C5 epimerization. The second hypothesis
is that DdahB could have less flexible conformation of the active site than MlghB.
Several studies have shown that homologous enzymes with conserved active site
sequences can perform different catalysis (17, 53, 138). This feature was referred to
as active site flexibility, which allows specific enzymes to perform specific functions
based on the conformational changes that occur upon substrate binding or during the
catalysis (89, 180).
To look for possibility of side chain conformational changes and
compensation upon mutation, the mutants were also modeled. The mutants’ models
were obtained by modeling the mutated protein sequence in SWISS-MODEL rather
than replacing the side chain in the modeled wild type enzyme. The wild type model
was superimposed with each mutant model. Based on the superimposed structure, all
mutants’ models showed no differences in the highlighted residues’ conformation
compared to the wild type, except for two mutants of MlghB, Y134F and N121S.
Both mutants showed changes in the orientation of Tyr132 (Figure 12). This indicates
that Tyr132 could have a flexible orientation of its side chain.
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Table 3: SDM list for the epimerases:

Epimerases

DdahB

Mutation

N121S*
H67A
H67N
Y134F **
K74A

MlghB

N121S*
H67A*
H67N

Rational
Substrate
recognition
(binds O4)
Catalytic,
inactivate.
Catalytic,
inactivate.
Catalytic,
inactivate.
Catalytic,
inactivate.
Substrate
recognition
(binds O4)
Catalytic,
inactivate.
Catalytic,
inactivate.

Rational of the
substitution choice
Shorter with no
amide group and
conserved polarity.
No functionality.
Conserved polarity
Conserved structure
with no
functionality.
No functionality.
Shorter with no
amide group and
conserved polarity.
No functionality.
Conserved polarity
with no charge.
Conserved structure
with no
functionality.

Y134F*

Catalytic,
inactivate.

Y132F*

Catalytic,
inactivate.

Conserved structure
with no functionality

K74A

Catalytic,
inactivate.

No functionality.

*SDM done by Michael Roubakha, 2013
** SDM done by Chelsea Kubinec, 2015
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Figure 10: The tertiary and quaternary structure model for the epimerases
compared to the crystallography structure of RmlC. A. Ribbon representation of
the superimposed structure model for both DdahB and MlghB shown as a dimer
where (A) monomer is in yellow and (B) monomer is in blue. N and C annotate the N
and C termini respectively. The sugar-nucleotide binding site in both monomers is
indicated by a double arrow. B. Ribbon representation of RmlC crystallography
structure from S. enterica in gray ribbon with dTDP-phenol, a substrate analog, in
orange spheres (PDB code 1DZR).
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Figure 11: The epimerases binding site structure model compared to the binding
site of RmlC. Ribbon and stick representation of the residues that are predicted to be
involved in catalysis or substrate binding A. DdahB model B. MlghB model. No obvious
differences were noted between the conserved residues in the binding site of both DdahB
and MlghB. C. The binding site structure of RmlC from S. enterica (PDB code 1DZR).
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Figure 12: MlghB mutants structure model. Ribbon and stick representation of
the superimposed structure of MlghB WT in cyan, and mutants in red. A. Change
of Tyr132 orientation in Y134F mutant. B. Change of Tyr132 orientation in N121S
mutant.
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3.2.4. Crystallography:
The crystallography data was obtained from Laura Woodward (Dr. James
Naismith, St. Andrews University, UK). Both DdahB and MlghB crystal structures are
solved by molecular replacement using S. enterica’s RmlC crystallography data. The
resolution of DdahB and MlghB structures is 1.9 Å and 2.3 Å, respectively. There was no
difference in the location and orientation of the conserved residues between DdahB and
MlghB binding sites except for the Asp173, which could form a chemical dyad with
His67 (Figure 13). In DdahB, Asp173 is conserved in the protein sequence but its
location is not conserved. If this His67/Asp173 dyad is important for C5 epimerization,
this may explain why DdahB cannot perform it like MlghB. By overlying the
crystallography structure with the modeling by superimposing both structures , it can be
concluded that the homology modeling approach is feasible to identify the overall
structure of the enzymes active sites. However, the limitation is the slight inaccuracy of
some side chains orientation, such as Tyr132, Tyr134, and Asn121. MlghB was cocrystallized with GDP-mannose as an analog substrate to identify the possible substrate
binding residues (Figure 13-C) (Figure 15). The electron density map of the mannose ring
was not included in the final structure because it can occupy a wide range of positions in
the binding site resulting in a very low electron density map, but the GDP portion could
be detected. MlghB/GDP-mannose co-crystal structure revealed the possible interaction
of the residues highlighted in Table 2 with the substrate. In addition, it sheds light on
residues that bind the GDP, Ile32, Tyr142, Lys54, and Phe24. Additional residues were
identified including Asp144 and the N-terminus of the B monomer Met1 (Figure 15).
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Figure 13: The epimerases binding site crystallography structure (Laura
Woodward and Dr. James Naismith). Ribbon and stick representation of the residues
in the sugar-nucleotide binding site. A. DdahB binding site. B. MlghB binding site. C.
Side view of MlghB binding site with the GDP molecule in orange, showing the
residues that could be involved in the catalysis and substrate binding.
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Figure 14: Comparison between the modeling and the crystallography structures of
the binding site of the epimerases. The right panel shows the modeling while the left
panel shows the crystallography structures (Laura Woodward and Dr. James Naismith)
of DdahB and MlghB binding site. One of the differences observed is the DdahB
Asp173 that is not conserved in location as shown in crystallography. The other
difference is the orientation of the side chains of some residues.
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Figure 15: GDP binding in MlghB. The structure of MlghB and MlghB/GDP-mannose
(Laura Woodward and Dr. James Naismith). A. MlghB structure docked with GDPmannose electron density map in gray net. B. MlghB/GDP-mannose co-crystal structure.
GDP molecule is in orange. The loop and the residues that are involved in GDP binding
are in purple. N annotates the N-terminal end of MlghB.
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3.3.

Reductases comparative functional analysis and structure:

3.3.1. Comparative functional analysis:
The analysis of the active site of the C4 reductases, DdahC and MlghC, was based
on the knowledge obtained from GFS, GDP-4-keto-6-deoxy-D-mannose C3/C5
epimerase, C4 reductase, from E. coli (99, 157, 158). The remarkable feature of GFS
enzyme is its ability to catalyze three distinct reactions within a single active site to
generate GDP-L-fucose. These include epimerizations at C3 and C5, as well as an
NADPH-dependant reduction at C4 of the 4-keto substrate (99). The initial step is
deprotonation at C3 from one face followed by reprotonation on the other face of the
sugar ring to generate the first product. This product is then epimerized at C5 by
deprotonation from one face and reprotonation from the other. Finally, an NADPHdependant reduction converts the C3/C5 epimer into GDP-L-fucose by converting the C4
carbonyl into a hydroxyl group (99). Based on crystallography, GFS is a member of the
short-chain dehydrogenase reductase (SDR) family (79). The substrate binding domain
include a pocket forming hydrophobic residues to bind the GDP, Leu184, Val201, and
Val180, as well as Trp202 that moves after the substrate binding to cover this pocket (99,
157). GFS possesses the catalytic triad, Ser107, Tyr136, and Lys140 (SYK), which is
characteristic of SDR enzymes (79). Tyr136 protonates the C4 carbonyl during the
reduction step (99). The Ser107 and Lys140 are important to lower the pKa of the
catalytic Tyr136, which allows it to function as a general acid or base during catalysis
(157). In addition, two catalytic residues that are not conserved among SDR members
were identified by modeling coupled with mutagenesis, Cys109 and His179. Both
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residues are implicated in the epimerization reaction (99). Other residues were predicted
to interact with the sugar ring based on structural modeling, Ser108 and Asn165.
However, their role in catalysis is unknown.
DdahC and MlghC are predicted to be C3/C5 epimerases and C4 reductases.
However, based on biochemical studies conducted in our lab, it has been shown that they
only perform the C4 reduction on the already epimerized 4-keto form of GDP-mannoheptose (111). Based on sequence alignment of E. coli GFS with C. jejuni reductases,
DdahC and MlghC substrate binding domain contain the hydrophobic residue that make
the GDP binding pocket, Ile185, Ile231, and Val181, as well as Trp232 that could be
involved in covering the substrate after binding as observed in GFS (DdahC numbering).
The substrate binding domain of DdahC possesses the same SYK catalytic triad that
found in GFS, Ser108, Tyr137, and Lys141 (DdahC numbering). However, MlghB has
both Lys140 and Ser107, but not the tyrosine residue of the triad (MlghC numbering).
Instead, a phenylalanine was found based on the sequence alignment (Figure 16) (Table
4). Aligned with the His179 and Cys109 in GFS, which are predicted to be catalytic
residues for the epimerization, DdahC has His180 and Thr110 while MlghC has Arg181
and Tyr109. The residues that are predicted to interact with the sugar ring are Asn166 and
Thr109 in DdahC, Asn165 and Gly108 in MlghC. The hydrophobic guanidine pocket
forming residues are found in both DdahC and MlghC. The sequence alignment also
showed that there is an extra sequence of 29 amino acids in DdahC and MlghC not found
in GFS, which could correspond to a specific structural motif (Figure 16).
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It has been shown that DdahC and MlghC are highly specific in their choice of
substrate, and both generate different products (111). The fact that the catalytic residues
are not conserved between DdahC and MlghC suggests that they could be involved in the
substrate and products specificity. Therefore, the catalytic residues in DdahC His180 and
Thr110 have been targeted for mutagenesis to test their role in specificity. Although
these residues are predicted to catalyze epimerization reactions, DdahC and MlghC do
not perform epimerization reaction on their substrates (111). Thus, His180 and Thr110
could be only involved in substrate binding and specificity.
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Table 4: Comparative functional analysis of the conserved residues in the reductases
binding site:

GFS
E. coli

Function (99)

S107
Y136

Catalytic triad for
reduction at C4

K140
C109

H179
S108
N165

In suitable position
as a general acid or
base for the
epimerization at C3
and C5.
Predicted to interact
with the sugar ring

L184
V201
V180

Hydrophobic pocket
for the guanidine
ring of the
nucleotide

W202

G67

Unknown

DdahC
C. jejuni

MlghC
C. jejuni

S108

S107

Y137

F136

K141

K140

T110

Y109

Predicted function
Catalytic triad in
DdahC. M110
instead of F136 in
MlghB based on the
structure.

Catalytic
H180

R181

T109

G108

N166

N165

I185

L184

I1231

I230

V181

V180

W232

W233

G68

C68

Interact with the
sugar ring

Hydrophobic pocket
for the guanidine ring
of the nucleotide

Located close to the
co-factor. Could be
important for
binding.
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Figure 16: Protein sequence alignment of the reductases. Alignment of GFS from E.
coli with C. jejuni reductases DdahC and MlghC protein sequence. The residues of
interest are highlighted, and the numbering is for DdahC. In red box is the 29 amino acid
sequence that is found in C. jejuni reductases but not in GFS.
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3.3.2. Reductases structure modeling:
Within the highest QMEAN scoring templates for DdahC and MlghC, the GDP-4keto-6 deoxy-mannose C3/C5 epimerase, C4 reductase GFS from E. coli was used as a
template (PDB code 1BSV) (157). The resolution of GFS structure is 2.20 Å. Both
reductases structures were similar to each other and existed as dimers (Figure 17).
Nevertheless, there were unstructured loops that are not found in the GFS structure
corresponding to the extra 29 amino acids sequence in both DdahC and MlghC. Based on
the structural alignment with GFS, both DdahC and MlghC have two domains, the cofactor binding domain and the substrate binding domain. The co-factor binding domain
was located by superimposing the structure with GFS/NADP+ co-crystal structure (Figure
17-B). The residues that are predicted to catalyze or to bind the sugar ring in the binding
site based on the functional analysis were highlighted (Figure 18).
Based on structural modeling, the catalytic triad is conserved in location in
DdahC compared to GFS, while in MlghC the tyrosine is substituted by phenylalanine
(Figure 18) (Table 4). There is no adjacent tyrosine in the active site that could function
as an alternative. However, Met110 was found close enough to form Ser106, Met110,
and Lys139 (SMK) catalytic triad that has been previously identified in a UDP-GlcNAc
C6-dehydratase, C4-reductase, WpbM (Figure 18-B) (40). In WpbM, the methionine
residue of the catalytic triad was shown to be essential for catalysis (40). In addition, a
cysteine residue, C68 that could be important for catalysis was found hanging on a loop
in close location to the active site in MlghC (Figure 18-B).
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Figure 17: The tertiary and quaternary structure model for the reductases. A.
Ribbon representation of the superimposed structure model for DdahC and MlghC.
Showed as a dimer where (A) monomer in yellow and (B) monomer is in blue. N and C
annotate the N and C termini respectively. The co-factor binding site in both monomers is
indicated by a double arrow. B. Ribbon representation of GFS from E. coli in gray ribbon
with the co-factor NADPH in orange spheres (PDB code 1BSV). DdahC and MlghC
overall structure resemble GFS structure except the unstructured loops.
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Figure 18: The reductases binding site structure model compared to the binding site
of GFS. Ribbon and stick representation of the residues that are predicted to be involved
in catalysis or substrate binding A. DdahC model superimposed with NADPH molecule
of GFS structure. B. MlghC model superimposed with NADPH molecule of GFS
structure. C. GFS/NADPH co-crystal structure from E. coli (PDB code 1BSV). DdahC
resembles GFS binding site more than MlghC.
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3.3.3. Site-directed mutagenesis:
For DdahC, four mutants were planned, three of which were generated by a
previous lab member. T110C mutant was generated to mimic GFS activity. H180R and
the double mutant H180R/T110Y mutants were generated to mimic MlghC activity.
Several attempts made to generate the single T110Y mutant failed. However, it will be
generated using reverse mutagenesis on the H180R/T110Y template to revert the mutated
His180. For MlghC, only one mutant was planned and generated, C68A, to test the
function of the cysteine in catalysis (Table 5).

Table 5: SDM list for the reductases:

Reductases

Mutation

Rational

Rational of the
substitution choice

DdahC

T110C

Catalytic, testing
specificity

Mimic GFS catalysis

Catalytic, testing
specificity

Mimic MlghC catalysis

Unknown
function

No functionality

H180R
H180R/T110Y

T110Y*
MlghC

C68A

All mutations in this table were made by Michael Roubakha, 2013
* Is to be generated.
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3.4.

Protein expression and purification:
The GDP-manno-heptose modifying enzymes, wild type and mutants, were

successfully purified using affinity chromatography purification (Figure 19). The
concentrations of the enzymes obtained by Bradford assay were optimized to have equal
concentration of the wild type and mutants as shown in Figure 19-D.

3.5.

Epimerases enzymatic assays and kinetics:
The enzymatic activity was tested for the wild-type and mutants of DdahB

(N121S, H67A, and H67N) and MlghB (N121S, H67A, H67N, and Y134F) at the same
enzymes concentrations following previously established conditions. The activity was
tested on GDP-manno-heptose (kindly provided by Dr. Creuzenet) to see if the mutants
fulfill their purpose of inactivating the enzyme if they are indeed catalytic residues. In
addition, they were tested on GDP-mannose substrate, which is a hexose-based sugar
nucleotide. Since our prediction for the residues’ function is based on the structural
modeling and the comparison to enzymes that use hexose-based substrate, it is important
to test the activity on such substrate. This analysis allows us to identify the residues that
are specific to GDP-manno-heptose modification.

3.5.1. Epimerases reactions on GDP-manno-heptose:
The activity of DdahB and MlghB wild type and the mutants was tested in three
independent experiments using two different purified enzymes stocks. For the mean data
of the three experiments’ integrations for DdahB and MlghB activity on GDP-mannoheptose see Appendix 4.
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Based on the in vitro pathway of GDP-manno-heptose modification, DdahB
epimerizes P1 at C3 to generate one product, which is P4α (Figure 20-A1). The DdahB
N121S mutant that was generated to investigate the function of the Asn in the substrate
recognition and thus in the catalysis showed no significant difference compared to the
wild type (Figure 21-A2). However, H67A and H67N mutants, which were predicted to
be catalytically inactive had produced P4α, but significantly less than the wild-type (p <
0.001) (Figure 21-A2).
On the other hand, MlghB is known to generate P4α, P4β, and P4γ by C3, C5,
and C3/C5 epimerization respectively as observed for the MlghB wild type (Figure 21B1). There is an inter conversion between the substrate P1 and MlghB products toward
P1 and P4γ. MlghB N121S mutant generated the same products with no significant
difference to the wild type (Figure 21-B2). The histidine mutants of MlghB, H67A and
H67N were unable to epimerize at C5 (no P4β or P4γ), but they could generate the C3epimer (P4α), although significantly less than the wild type (p < 0.001). The MlghB
Y134F mutant that was predicted to be catalytically inactive produced all the three
products, although significantly less P4α and P4β (p < 0.001 and p <0.01), respectively.
The kinetics of DdahB and MlghB were measured for the wild type and the
mutants for four time points. Due to the high efficiency of the enzymes, most of the
products were at their maximum production yield in 5 minutes with no further changes at
later time points (Figure 22). This experiment is to be repeated using lower enzymes
concentration to highlight the differences between the wild type and the mutants’
kinetics. Nevertheless, the results were interpreted from the currently available data set
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represented in Figure 22 with regards to differences in maximum product formation. For
DdahB C3-epimerization (P4α), N121S mutant seemed to have no significant difference
compared with the wild type (Figure 22-A). Both His67 mutants were significantly less
active. For MlghB C3-epimerization (P4α production), N121S mutant was 10% less
active than the wild type during the 20 min (Figure 22-B). Bothe MlghB His67 mutants,
as well as Y134F were significantly less active than the wild type. For MlghB C5 and
C3/C5-epimerization (P4β and P4γ production), N121S mutant was comparable to the
wild type. The Y134F mutant was almost inactive and was very slow. No P4β or P4γ
were detected for the His67 mutants.
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Figure 19: SDS-PAGE analysis of the purified GDP-manno-heptose modifying
enzymes. A. Purified GDP-manno-heptose modifying enzymes. From 1 to 5 showing,
DdahB (22 kDa), MlghB (22 kDa), DdahC (40 kDa), MlghC (41 kDa), and DdahA (40
kDa) respectively. B. An example of the affinity chromatography purification of the
His-tagged proteins. C. Purification of the GST-tagged HP0044 (73 kDa) by GSTrap
FF column. D. Optimized concentrations for the epimerases and reductases. All gels
were stained with Coomassie blue.
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Figure 20: In vitro experimental pathways for GDP-manno-heptose and GDPmannose modification. A. GDP-manno-heptose is dehydrated by DdahA generating P1.
DdahB epimerizes P1 at C3 to generate P4α in equilibrium. MlghB epimerizes P1 at C3
giving P4α, at C5 giving P4β, and at both C3 and C5 giving P4γ. The two directions
arrows indicate interconversion in MlghB reaction preferably towered P1 and P4γ.
DdahC reduces P4α at C4 to generate P5α. MlghC reduces P4γ at C4 to generate P5γ. B.
GDP-mannose is dehydrated by HP0044 to generate P1’. MlghB generates P4’ in
equilibrium by epimerization at unknown location. DdahC produces two products, PII
and PIII, from P1’ or P4’. MlghC produces only PI from either P1’ or P4’.
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Figure 21: CE electropherograms and peaks percentage areas highlighting the
activity of the epimerases, wild type and mutants, on GDP-manno-heptose. The
electeropherograms are example of one of the experimental repeats. For both panels (A1
and B1), a base reaction (trace b) containing 0.17 mM P1 was prepared by incubating the
GDP-manno-heptose (trace a) with 1.5 µmol DdahA and 0.13 mM NADP+ as an internal
standard. A1. The activity of 1.0 pmol DdahB wild-type and mutants on P1 for 30
minutes. B1. The activity of 1.0 pmol MlghB wild-type and mutants on P1 for 30
minutes. The specific products are highlighted in bold. * denotes a small impurity present
in the heptose preparation. Illustrative cartoon for the experimental pathway in the grey
box. Panels (A2 and B2) shows the peaks percentage areas of DdahB and MlghB
products for three independent experiments. * indicates (p < 0.01) and ** indicates
(p < 0.001). Statistics were done using T-test.
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Figure 22: Kinetics of the wild type epimerases and mutants’ activity on GDPmanno-heptose. The graphs represent the percentage area of the product to the total area
per reaction (Y-axis) for four time points over 20 minutes (X-axis) A. DdahB C3epimerization (P4α). B. MlghB C3-epimerization (P4α). C. MlghB C5-epimerization
(P4β). D. MlghB C3/C5-epimerization (P4γ). Each reaction contains 0.17mM substrate
and 1.0 pmol enzyme. After Incubation, the samples were snap frozen in dry ice/ethanol
at each time point and analyzed by CE. (Preliminary experiment). To be repeated with
lower enzymes concentration to avoid the equilibrium at the first time point.
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3.5.2. Epimerases reactions on GDP-mannose:
It was established previously in our lab that the GDP-manno-heptose modifying
enzymes act less efficiently on GDP-mannose substrate than on GDP-manno-heptose
(111). DdahA that was used as the dehydratase to generate the 4-keto substrate for the
epimerases from GDP-manno-heptose has a very poor activity on GDP-mannose, as
longer incubation and higher enzyme concentration is needed to generate the 4-keto
product (110). Therefore, HP0044, a GDP-mannose dehydratase from Helicobacter
pylori, was used due to its high efficiency in the formation of P1’ (31). Based on the
preliminary pathway for GDP-mannose, MlghB and DdahB can generate one single and
identical product (P4’) but with different efficiencies (Figure 20-B). MlghB formation of
P4’ is in equilibrium with P1’. P4’ could be an epimerized product, but the epimerization
status and location onto P4’ are unknown. Two hypotheses can be proposed. The first
hypothesis is that P4’ is a C3 epimer, because both MlghB and DdahB can perform C3epimerization, thus generating the same product. However, the single C3-epimerization is
only proven for the heptose substrate, and MlghB and DdahB could function differently
on a hexose-based substrate. The second hypothesis is that P4’ could be a double epimer,
similar to RmlC, which releases a single product, a C3/C5 epimer from a hexose-based
substrate. However, this requires both DdahB and MlghB to perform C3/C5
epimerization. Unfortunately, P4’ cannot be identified by mass spectrometry because of
its unstable nature as a 4-keto sugar.
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In this analysis, the activity of the DdahB and MlghB wild type and mutant are
tested on P1’ that is the dehydrated form of GDP-mannose in two independent
experiments using two different purified enzymes stocks. For the mean data of the two
experiments’ integrations for DdahB and MlghB activity on GDP-mannose see
(Appendix 5). GDP-mannose was incubated with HP0044 to generate P1’ as well as
either DdahB or MlghB wild type or mutants. MlghB reactions are incubated for one
hour. The results showed that MlghB N121S mutant generated the same product as the
wild type with no significant difference (Figure 23-B1,B2). However, H67A and H67N
were catalytically inactive. Y134F mutant was significantly less active than the wildtype, but generated the same P4’(p < 0.01) (Figure 23-B2).
The kinetics showed that at later time points, the N121S mutant produced slightly
more P4’ than the wild-type, and the Y134F mutant produced almost the same amount of
P4’ as the wild type but in a slower manner (Figure 24-A). The product degradation was
measured during the kinetics and showed equal degradation in the wild type and the
mutants’ reactions (Figure 24-B). This indicates that the differences in P4’ formation
between the wild type and the mutants was due to the mutation rather than the
degradation of the substrate. After 5 hours, 50% of the substrate was degraded. The
activity of the wild type MlghB on GDP-mannose substrate was slower and less efficient
than its activity on GDP-manno-heptose, which suggests that MlghB possesses
specificity toward GDP-manno-heptose.
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The activity of DdahB was tested with five times the enzyme concentration and
five times longer incubation time (5 hours) compared to MlghB. The wild-type had very
little activity, and activity was almost undetectable for the DdahB mutants (Figure 23-A).
No kinetics was performed for DdahB on GDP-mannose due to the insufficient product
formation and the high substrate degradation observed over time. In contrast to the
efficient activity of DdahB on GDP-manno-heptose substrate, DdahB had undetectable
activity on GDP-mannose even at higher enzyme concentration. This difference indicates
that DdahB has specificity to GDP-manno-heptose rather than GDP-mannose.
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Figure 23: CE electropherograms and peaks percentage areas highlighting the
activity of the epimerases, wild type and mutants, on GDP-mannose. The condition
of the reactions and incubation times are different between DdahB and MlghB. A. The
activity of 5.0 pmol of the wild type DdahB and the mutants on P1’ after 5 hours
incubation at 37°C. To generate P1’, a base reaction containing 0.77mM GDP-mannose,
2.0 pmol HP0044, and 0.1 mM NADP+ was incubated at 37°C for 90 minutes (trace a).
B1. The activity of 1.0 pmol of the wild type MlghB and the mutants on P1’ after one
hour incubation at 37°C. To generate P1’, a base reaction containing 0.77mM GDPmannose, 2.0 pmol HP0044, and 0.5 mM NADP+ was incubated at 37°C for 90 minutes.
NADP+ was used as an internal standard. Illustrative cartoon for the experimental
pathway in the grey box. B2. Shows the peaks percentage areas of MlghB products for
two independent experiments. * indicates (p < 0.01) and ** indicates (p ≤ 0.001).
Statistics were done using T-test.
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Figure 24: Kinetics of MlghB wild type and mutants’ activity on GDP-mannose. The
graph represents the percentage area of the product to the total area per reaction (Y-axis)
for four time points over 20 minutes (X-axis). Each reaction contains 0.4mM substrate
and 1.0 pmol enzyme. After Incubation, the samples were snap frozen in dry ice/ethanol
at each time point and analyzed by CE. A. The kinetics of P4’ formation by the wild type
MlghB and the mutants. B. The degradation of the substrate over time (P2). The substrate
was equally degraded in the wild type and the mutants’ reaction to 50% at the end of the
kinetics. (Preliminary experiment). To be repeated to confirm the kinetics differences
detected between the wild type and the mutants.
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3.6.

Reductases enzymatic assays and kinetics:
The activity and the substrate specificity of the reductases were tested for DdahC

(T110C, H180R, and H180R/T110Y) and MlghC (C68A) compared to the wild type on
heptose or mannose-based substrates. The epimerized products of the dehydrated GDPmanno-heptose, P4α, P4β, and P4γ, were used as substrates to test the specificity of the
mutated reductases. On the other hand, both the dehydrated (P1’) and the epimerized
(P4’) forms of GDP-mannose were used as substrates to test the activity and product
formation of the wild type. This analysis was performed to test the involvement of the
mutated residues in either the activity or the substrate specificity of the reductases. It was
also done to determine if the reductases would function differently on a mannose-based
substrate rather than their heptose substrate.

3.6.1. Reductases reactions on GDP-manno-heptose:
The epimerized products of the GDP-6-deoxy-D-altro-heptose, P4α, P4β, and
P4γ, were generated using MlghB, which can generate them in equilibrium, to test the
activity and the substrate specificity of the reductases mutants. The activity and the
substrate specificity of DdahC and MlghC have been established previously (111).
Although they were predicted as C3/C5-epimerases, C4 reductases, they only perform
NADPH-dependent reduction of their epimerized substrates at C4 generating different
products. DdahC reduces the C3-epimer (P4α) into P5α, which is the end product of
GDP-manno-heptose modification pathway in C. jejuni 81-176. MlghC reduces the
C3/C5-epimer (P4γ) to generate P5γ.
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The general activity of DdahC and MlghC mutants was tested in two independent
experments. For data integration see Appendix 6. No statistics were done for the
reductases activity on GDP-manno-heptose because no repeats were done for each of the
two experiments because the experimental conditions were different. The first experment
was done using a reaction where MlghB was still available in the mix to continuously
generate the three epimerized substrates throughout the reaction. The activity was
interpreted from the formation of the reduced product, and the conversion of NADPH
into NADP+. DdahC mutants, T110C generated 50% more P5α than the wild type with
total conversion of NADPH. H180R mutant had the same production of P5α as the wild
type (Figure 25-A). However, the double mutant H180R/T110Y was catalytically
inactive. On the other hand, MlghC C68A had 10% lower activity than the wild type in
the formation of P5γ with total conversion of NADPH into NADP+ (Figure 25-A).
Despite the differences in the activity, the active mutants were able to generate the
specific product just like the wild type, indicating that there is no change in the specificity
of the products formed. However, the substrate specificity cannot be interpreted from this
experiment set because all the substrates are being resupplied from P1 by MlghB that was
still in the reaction.
The second experiment was done using a reaction where MlghB was ultrafiltered
after the generation of the three epimerized substrates, P4α, P4β, and P4γ to test the
reductases mutants’ substrate specificity. The T110C mutant of DdahC showed more P5α
formation than the wild type with an increase in NADP+ (Figure 25-B). H180R showed
slightly less activity than the wild type. H180R/T110Y was catalytically inactive.
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Changes in P4α were undetectable compared to the MlghB control reaction (Figure 25-B,
trace a). Unfortunately, the MlghB control trace was obtained from an aliquot withdrawn
before the ultrafiltration, which results in further interconversion of P4α into P1 as shown
by the integration. Therefore, we could not interpret differences in the substrate
utilization by the reductases by using MlghB reaction as a control. However, we used the
inactive mutant H180R/T110Y reaction as a virtual control. A slight decrease in P4α was
observed in the wild type DdahC and the active mutants, while a corresponding increase
in P5α was observed. More decrease in P4α level was observed for T110C mutants as a
result of the formation of more P5α. No change was observed in P4γ for all DdahC
mutants. P4β was undetectable because it usually migrates with NADP+. For MlghC, the
C68A mutant was less active than the wild type and showed the same substrate
specificity as the wild type. A decrease in P4γ upon formation of P5γ was observed for
MlghC wild type and C68A mutant, indicating that there is no change in the substrate
specificity for the mutant.
The kinetics of the wild type DdahC and MlghC were performed in the same way
where MlghB was ultrafiltered from the reaction before adding the reductases. The
results are interpreted as percentage of the products area to the total area of the product
and substrate (Figure 26). With regards to the activity of DdahC and MlghC mutants, the
results confirmed that T110C mutant was two times more active than the wild type, while
H180R showed no difference. The double mutant H180R/T110Y was inactive even with
longer incubations (Figure 26-A). The kinetics showed that the gradual increase in P5α
formation is related to a gradual reduction in P4α, meaning that there was no change in
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the substrate specificity of DdahC mutants. On the other hand, MlghC C68A mutant had
comparable activity to the wild type at early time points but less activity after an hour of
incubation with no change substrate specificity (Figure 26-B).
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Figure 25: CE electropherograms highlighting the activity of the reductases, wild
type and mutants, on GDP-manno-heptose. A. The reductases activity in the presence
of MlghB which can continuously supply P4α, P4β, and P4γ to the reductases as long as
the P1 substrate is available. This allows testing the level of the activity of the wild type
and the mutants. P4β was very difficult to resolve, as it often co-migrates with NADP+. A
base reaction containing the three epimerized substrates (P4α, P4β, and P4γ) was
generated to test the activity and the specificity of the reductases by incubating MlghB
with 0.17 mM of freshly synthesized P1 out of GDP-manno-heptose (trace a) and 0.5mM
NADPH. To that, 1.0 pmol of either DdahC and MlghC wild type or mutants was added
and incubated for 30 minutes. DdahC reduces P4α into P5α, while MlghC reduces P4γ
into P5γ. B. The reductases activity on fixed amounts of the preformed P4α, P4β, and P4γ
substrate. This was done to facilitate determination of the substrate specificity of the
mutants. A base reaction was set up using MlghB and 0.37 mM of freshly synthesized P1
to generate the three epimerized substrates (Trace a). It also contained 0.5mM NADPH.
This reaction was ultrafiltered (red dash line) to remove MlghB. Either DdahC or MlghC,
wild type or mutants, was added to the filtrate and incubated for 30 minutes. The specific
products are highlighted in bold. There is no change in the specificity of the mutants. *
denotes a small impurity in the NADPH or the GDP-manno-heptose stocks. Illustrative
cartoon for the experimental pathway in the grey box. See Appendix 6 for peaks
integrations.
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Figure 26: Kinetics of the reductases wild type and mutants on GDP-mannoheptose. The graphs represent the percentage area of the reduced product to the total area
of the substrate and the product per reaction (Y-axis), for seven time points over an hour
(X-axis). A. DdahC C4 reduction of P4α. B. MlghC C4 reduction of P4γ. A base reaction
containing 0.5mM NADPH and 0.37 mM of freshly synthesized P1 was incubated with
MlghB to generate the epimerized substrates. This reaction was ultrafiltered to remove
MlghB. Then it was equally divided in aliquots to which 0.5 pmol of each reductase was
added. After incubation, the samples were snap frozen in dry ice/ethanol at each time
point and analyzed by CE. (Preliminary experiment).
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3.6.2. Reductases reactions on GDP-mannose:

Preliminary data from our lab of the activity of DdahC and MlghC on GDPmannose substrate showed that they can use P4’, which is suspected to be epimerized, to
generate different products. Two products were identified for DdahC, PII and PIII, while
one product was observed for MlghC, PI. The nature of the theses products whether
epimerized or reduced is unknown. In this analysis both the dehydrated (P1’) and the
epimerized (P4’) forms of GDP-mannose were used as substrates to test the activity and
the products formed by the wild type.
There are two major limitations of this analysis. The first is, because the heptose
modifying enzymes, DdahC and MlghC, are less efficient on such substrates, longer
incubation is needed to reach detectable levels of the products. However, both substrates,
P1’ and P4’, are 4-keto sugar nucleotides, and they degrade rapidly during long
incubations. Therefore, very small amounts of DdahC and MlghC products can be
detected above the baseline. The second is that DdahC and MlghC products migrate
closely to the substrate in the CE analysis. DdahC PIII migrates as a left shoulder peak to
the substrate P1’. DdahC’s PII migrate as a right shoulder peak to GDP-mannose, while
MlghC’s PI migrates as a left shoulder to GDP-mannose. This close migration of the
products to the substrates limits the measurement of the products formed. Therefore, it is
difficult to interpret the differences between the wild type and the mutants. An efficient
HP0044 enzyme should be used to completely convert GDP-mannose into P1’ to avoid
any overlap between peaks and any confusion in peak assignments.
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The first set of DdahC and MlghC wild type enzyme analysis was performed on
both P1’ and P4’ (Figure 27). One part of this set was performed where GDP-mannose
was incubated with HP0044 and MlghB, to generate P1’ and P4’, as well as each of
DdahC or MlghC. MlghB reaction is an equilibrium reaction, meaning that it can
constantly make P4’ out of P1’ as long as P1’ is available. Upon incubation with the wild
type reductases, DdahC generates PII and PIII, while MlghC generates PI (Figure 27A1). The co-injection of DdahC and MlghC reactions confirms that these products are
different (Figure 27-A2). Despite the fact that P4’ is assumed to be used by the
reductases, there were detectable levels of P4’ substrate in DdahC and more in MlghC
reactions. This could be from the activity of MlghB that continuously regenerates P4’
from P1’. P1’ can also be regenerated from GDP-mannose by the activity of HP0044 that
was also available in the reaction, which explain the disappearance of GDP-mannose
peak in both DdahC and MlghC reactions (Figure 27-A1). The second part is performed
where both HP0044 and MlghB were sequentially removed from the reaction after the
generation of their products. The filtrate, containing P1’ and P4’ without the enzymes,
was used to add either DdahC or MlghC. Upon incubation with the reductases, both
enzymes generate their specific products, PII and PIII for DdahC, and PI for MlghC, with
total conversion of both P1’ and P4’. This indicates that DdahC and MlghC can use both
P1’ and P4’. In addition, NADPH was totally converted into NADP+ (Figure 27-B).
The second set of the analysis was to test if they can use P1’ by itself (Figure 28).
GDP-mannose was incubated only with HP0044 to generate P1’. Upon incubation with
DdahC and MlghC, both reductases were able to generate their specific products from
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P1’ (Figure 28-A). For total conversion of GDP-mannose, HP0044 was incubated for two
hours resulting in more degradation of P1’ and formation of an unknown peak. This
unknown peak migrates similarly to P4’. To make sure that this unknown product was
not used by the epimerases instead of P1’, a similar experiment set was performed using
newly purified HP0044 to aid the total conversion of GDP-mannose in shorter incubation
time. Using newly purified HP0044 was necessary as it seems that HP0044 loses some of
its activity upon long storage. HP0044 was removed from the reaction after total
conversion of the GDP-mannose, and DdahC or MlghC were added to the filtrate. Upon
incubation, both DdahC and MlghC generate their specific products in the absence of the
unknown peak (Figure 28-B). All P1’ was used by DdahC to generate PII and PIII, while
some is left in MlghC reaction.
The activity and product specificity of the mutants were tested on P1’ using the
same conditions (Figure 29). Unlike the activity on heptose substrate, T110C mutant
generates both products, PII and PIII, but less than the wild type. However, H180R
mutant shows similar activity to the wild type generating PII and PIII. H180R/T110Y is
catalytically active and shows less activity than the wild type. On the other hand, MlghC
product peak is very small and close to the baseline. However, there is no difference
between the wild type and C68A mutant (Figure 29).
The kinetics of DdahC and MlghC wild type and mutants were performed where
both MlghB and HP0044 were available in the reaction. The results interpreted for the
percentage of the products area to the total area of all products and substrates, P1’ and
P4’ (Figure 30). For DdahC’s PII product, T110C mutant is significantly slower than the
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wild type, while H180R mutant was equivalent to the wild type in the early time points.
At late time points, PII was undetectable for H180R mutant (Figure 30-A). The kinetics
for H180R/T110Y was not performed at the time of this experiment. DdahC’s PIII
kinetics was not included. PIII was undetectable at most of the time points because of the
low resolution from the migration with the substrate P1’. On the other hand, MlghC’s PI
product was also undetectable at early time points. C68A mutant was significantly slower
than the wild type and generated less PI (Figure 30-B).
3.7.

Summary of the enzymatic assays and kinetics:
The enzymatic activity and the kinetics results of GDP-manno-heptose wild type

and mutated epimerases and reductases are summarized in Table 6.
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Figure 27: CE electropherograms highlighting the activity of the reductases on the
dehydrated and the epimerized product of GDP-mannose (P4’). A. DdahC and
MlghC can generate their products either from the dehydrated form (P1’) or the
epimerized form (P4’) of GDP-mannose (Trace c, d). A base reaction where GDPmannose was incubated with HP0044 and MlghB to generate both P1’ and P4’ in
equilibrium was used to test the activity of the reductases. P1’ is degraded over time into
P2. Incubation with DdahC generates two products (PII and PIII) (trace c), while
incubation with 1.5 pmol of MlghC generates only one (PI) (trace d). However, left over
substrates were observed. Because the products migrate close to each other and to the
substrate, both reactions were co-injected to show that they are different (Trace e),
zoomed out in the red box. * denotes a small impurity in the NADPH stock. B. Confirms
that the reductases are using both P1’ and P4’ due to the disappearance of their
corresponding peaks (trace b, c). No regeneration of P1’ and P4’ was observed because
both HP0044 and MlghB were ultrafiltered from the reaction (red dash lines) before
adding the reductases. Illustrative cartoon for the experimental pathway in the grey box.
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Figure 28: CE electropherograms highlighting the activity of the reductases on the
dehydrated product of GDP-mannose (P1’). A. The activity of DdahC and MlghC on
P1’ only. P1’ was synthesized from GDP-mannose by incubation with HP0044 for 2
hours (trace b). P1’ is degraded over time into P2. After total conversion of GDPmannose into P1’, the reaction was divided and each of the reductases was added
separately along with NADPH. Incubation with DdahC generates two products (PII and
PIII) (trace c), while incubation with MlghC generates only one (PI) (trace d). Because
the products migrate close to each other and to the substrate, both reactions were coinjected to show that they are different (Trace e), zoomed out in the red box. * denotes a
small impurity in the NADPH stock. # denoted an unknown product that results from
long incubation of HP0044. B. The unknown product (#), shown in panel A is indeed
from longer incubation of HP0044, and it is not used by the epimerases. After total
conversion of GDP-mannose into P1’ by newly purified HP0044 in 60 minutes (trace a),
the reaction was ultrafiltered to remove HP0044. This was divided and each of the
reductases was added (trace b, c). No formation of the unknown product (#) and less
degradation of P1’ is seen. Also, both DdahC and MlghC made their products using P1’.
Illustrative cartoon for the experimental pathway in the grey box.
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Figure 29: CE electropherograms highlighting the activity of the reductases wild
type and mutants on the dehydrated product of GDP-mannose (P1’). The activity of
the wild type DdahC and MlghC and the mutants on P1’. P1’ was synthesized from GDPmannose by incubation with HP0044 for 60 minutes (trace a), the reaction was
ultrafiltered to remove HP0044. This was equally divided and each wild type or mutant
was added separately. There was very little products formation due to an insufficient
amount of the substrate. * denotes a small impurity in the NADPH stock. Illustrative
cartoon for the experimental pathway in the grey box.
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Figure 30: Kinetics of the reductases wild type and mutants’ activity on GDPmannose. P1’ and P41 were the substrates for this set. Representing the percentage area
of the product to the total area of sugar nucleotides per reaction (Y-axis) for six time
points over 95 minutes (X-axis). A. The formation of PII product of DdahC. B. The
formation of PI product of MlghC.
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Table 6: Summary of the enzymatic assays and kinetics of the mutants compared to
the wild type epimerases and reductases.

Epimerases

DdahB

MlghB

Mutation

Rational

On GDP-mannoheptose
substrates

N121S*

Substrate
recognition
(binds O4)

No significant
difference in P4α
formation

H67A

Catalytic,
inactivate.

significantly less
P4α (p < 0.01)

H67N

Catalytic,
inactivate.

significantly less
P4α (p < 0.01)

N121S*

Substrate
recognition
(binds O4)

No significant
difference in P4α,
P4β, or P4γ

H67A

Catalytic,
inactivate.

No P4β or P4γ.
And significantly
less P4α
(p < 0.001)

Catalytic,
inactivate.

No P4β or P4γ.
And significantly
less P4α
(p < 0.001)

Catalytic,
inactivate.

Significantly less
P4α and P4β
(p < 0.001 and <
0.01), respectively

H67N

Y134F

On GDPmannose
substrates

UD

No significant
difference in
P4’

Inactive

Significantly
less P4’
(p < 0.01)
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Reductases

DdahC

Mutation

Rational

On GDP-mannoheptose
substrates

T110C

Catalytic,
testing
specificity

No change in
specificity.
50% more P5α
(faster)

20% less PII
(slower).

No change in
specificity.
P5α similar to WT

PII is similar to
WT.

Inactive

Active

No change in
specificity.
10% less P5γ
(slower)

70% less PI
(slower)

H180R
H180R/T
110Y
MlghC

C68A

Catalytic,
testing
specificity

Unknown
function

On GDPmannose
substrates *

UD: undetectable. DdahB WT is not efficient on GDP-mannose substrate.
C3, C5, C3, 5 indicate the epimerization sites.
* Results listed based on the kinetics. The percentages of the differences in the activity
are for the last time points (Figure 30).
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3.8.

Biofilm assay:
The wild-type strain, C. jejuni NCTC11168, was tested for biofilm formation

along with four heptose biosynthesis mutants and a capsule-less mutant that were
generated previously in our lab: wcaG::cat, mlghC::cat, mlghB::cat, wcaGΔ::cat, and
kpsM::kan (184). The kpsM::kan, a capsule-less strain, was used as a negative control as
the capsule was thought to have a role in biofilm formation (178). All the other mutants
have intact capsule except that it is devoid of the methylated heptose that is found in the
wild type (184). The wcaGΔ::cat mutant has deletions of the precursor GDP-mannoheptose synthesis genes (cj1423c- cj1425c), the heptose methyl transferase gene
(cj1426c), and other capsule MeOPN transferases genes (cj1421c and cj1422c).
Therefore, wcaGΔ::cat mutant contains the capsule backbone with no modifications, no
heptose, no methylation, and no MeOPN (184). The formation of biofilm by the wild
type and the mutants was measured every day for four days after an initial incubation.
The biofilm formation was tested under aerobic conditions, which are more relevant for
the survival of the organism in the environment. It has been shown that C. jejuni’s
biofilm formation increases under aerobic conditions (146). Perhaps it helps to minimize
the oxygen concentration for survival. The biofilm formation was also tested under
microaerobic conditions, which are the favorable conditions for C. jejuni growth. This
was done to confirm that the wild type C. jejuni does not need to make more biofilm
under microaerobic conditions. Also to investigate whether lacking the modified heptoses
would stress the bacterial cells and drive them to make more biofilm than the wild type
under microaerobic conditions.
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Under aerobic conditions, the wild type C. jejuni NCTC11168 made significantly
more biofilm than the negative control, kpsM::kan strain, at all detection days (p< 0.001)
(Figure 31). In addition, the amount of C. jejuni NCTC11168 biofilm has increased
significantly at the last day compared to the first day (p< 0.001) (Figure 31).
Comparing the biofilms formed by the mutants to the wild type at each detection
day showed that the wcaG::cat mutant had significant reduction in the biofilm amount at
the first day (p< 0.004), as well as at the following days (p< 0.001). The wcaG::cat
mutant made significantly more biofilm at the last day of detection compared to the first
day (p< 0.001). The mlghC::cat mutant’s biofilm was significantly less than the wild
type at all detection days (p< 0.001), and comparable to the negative control kpsM::kan at
the first three days. There was an increase in biofilm in the last day compared to the first
day of detection (p< 0.002). The mlghB::cat mutant’s biofilm was also significantly less
than the wild type (p< 0.001), and comparable to the negative cotrol kpsM::kan at all
detection days. No difference was observed in the biofilm between the first and the last
days of detection. The wcaGΔ::cat mutant had significantly less biofilm than the wild
type at all days of detection (p< 0.001). The biofilm of wcaGΔ::cat mutant was
comparable to the negative control at the first two days of detection. There was a
significant increase in the wcaGΔ::cat mutant’s biofilm amount at the last day compared
to the first day of detection (p< 0.001) (Figure 31).
In microaerobic condition, C. jejuni NCTC11168 wild type was able to make
significantly more biofilm than the negative control, kpsM::kan strain (p< 0.001) (Figure
32). The biofilm formed at all days of detection did not change. These results suggest that
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C. jejuni NCTC11168’s biofilm is indeed increasing under aerobic condition, but not
under microaerobic conditions.
The wcaG::cat mutant has significantly less biofilm than the wild type at the first
two days of detection (p< 0.001). However, the amount of biofilm at the last two days of
detection was comparable to the wild type. The difference between the first and the last
day of detection of wcaG::cat mutant’s biofilm was significant (p< 0.001), meaning that
unlike the wild type, wcaG::cat mutant’s biofilm was increasing.
There was no significant difference between the mlghC::cat mutant’s biofilm
amount and the wild type at all detection days, except at the second day where it was
significantly higher than the wild type (p< 0.001). The ammount of mlghC::cat mutant’s
biofilm at the first and the last day of detection was decreased (p= 0.004). Compared to
the increasing biofilm formed under the aerobic condition, mlghC::cat mutant behave
differently. It decreased under microaerobic condition, but increased under aerobic
condition.
There is no significant difference between mlghB::cat mutant and the wild type
biofilm amount at all detection days. The mlghB::cat mutant has no significant difference
between all days of detection. Compared to the aerobic biofilm, mlghB::cat mutant was
better at making biofilm under microaerobic rather under aerobic conditions, yet the
biofilm amount is not changing over days of incubation at both conditions.
Finally, the wcaGΔ::cat mutant’s biofilm amount was significantly less than the wild
type and comparable to the negative control at the first two days of detection. At the last
day of detection, the wcaGΔ::cat mutant’s biofilm amount had significantly increased
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compared to the first day of detection (p< 0.001) (Figure 32). Compared to the increased
biofilm formation under the aerobic condition, wcaG∆::cat mutant biofilm had increased
similarly under microaerobic condition.
The bacterial cell inoculums that were used in both experiments for each mutant
were analyzed for the quality of the capsule by SDS-PAGE using Hitchcock and Brown
method. After silver-staining, the SDS-PAGE showed that all the mutants, except the
capsule-less kpsM::kan mutant, have the capsule patterns that are found in the wild type
(Figure 33). The presence of the capsule in the heptose biosynthesis mutants indicates
that the differences in biofilm formation compared to the wild could be related to the lack
of the modified heptose in the capsule.
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Figure 31: Biofilm formation by C. jejuni NCTC 11168 wild type, as well as the
capsule and the heptose biosynthesis mutants under aerobic conditions. Biofilm
formation was measured every day for four days after the initial incubation under aerobic
conditions. Different letters indicate significant difference at (P≤0.001). Two letters
indicate no significance difference with either letters. Statistics were done using one-way
ANOVA test
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Figure 32: Biofilm formation by C. jejuni NCTC 11168 wild type, as well as the
capsule and the heptose biosynthesis mutants under microaerobic conditions.
Biofilm formation was measured every day for four days after the initial incubation under
microaerobic conditions. Different letters indicate significant difference at (P≤0.001).
Two letters indicate no significance difference with either letters. Statistics were done
using one-way ANOVA test.
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Figure 33: SDS-PAGE analysis of the capsule content of C. jejuni NCTC 11168 wild
type, as well as the capsule and the heptose biosynthesis mutants. The capsule (CPS)
and the lipooligosaccharide (LOS) fractions of cells samples prepared by Hitchcock and
Brown method. The gel was visualized by silver staining.

CHAPTER 4 - DISCUSSION
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4.1.

The substrates and products specificity of the epimerases:

DdahB and MlghB have specificity toward GDP-manno-heptose rather than
GDP-mannose substrate. DdahB epimerizes GDP-6-deoxy-4-keto-D-lyxo-heptose, P1,
only at C3 generating P4α, while MlghB epimerizes P1 as a surrogate substrate at C3,
C5, and both carbons generating three epimerized products, P4α, P4β, and P4γ. On the
other hand, using the dehydrated GDP-mannose substrate (P1’) to investigate the
specificity of the active site showed that DdahB and MlghB generate a single product of
unknown epimerization status (P4’), yet both are less efficiently active compared to the
activity on GDP-manno-heptose substrate. DdahB is even less efficient than MlghB, as it
failed to generate detectable products at higher enzyme concentration and longer
incubation time. The epimerization status of P4’ is unknown. To address what epimer P4’
is, P4’ should be identified using mass spectrometry combined with deuterium
incorporation analysis as done previously to characterize the heptose epimers in our lab
(112). However, this approach is not feasible due to the instability of P4’ and the
insufficient amounts that can be generated.

4.2.

Substrate binding and catalytic site of the epimerases:

The binding of the enzyme to the substrate is dominated by the nucleotide portion.
Therefore, the nucleotide binding determines the conformation that the ligand will adopt
in the enzyme active site (46). The dTDP-phenol adopts a U shape in RmlC rather than
extended conformation (34, 55). Whether there is a difference between dTDP and GDP
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nucleotides in term of the conformation of binding to the enzyme cannot be derived from
the data we have. However, the MlghB/GDP-mannose co-crystallography, although the
mannose ring was not included in the final figure, showed that the ligand could be fitting
in a U-shape in the binding site (Figure 15). The guanidine ring of the GDP moiety is
found between the N-terminus Met1 of the B subunit, Ile32, and Lys54 residues. Phe24 is
stacking against the ribose ring of the GDP. Other residues were identified that belong to
a loop that was unstructured in the non-bound MlghB (Figure 15). Upon GDP-mannose
binding, this loop, containing Tyr142 and Asp144, was shown to make a pocket for the
GDP moiety. This loop could be important in regulating the substrate/product route into
and out of the active site as observed in RmlC enzymes (34, 55, 60).
Based on the comparative functional analysis, the modeling and the
crystallography structures, as well as the mutagenesis, some of the functional residues
that are involved in the catalysis are identified in DdahB and MlghB.
The Asn121 residue is predicted to be important for binding the 4-keto group of
the substrate through the amide. This binding will lower the pKa value of the protons
attached to C3 and C5 to facilitate the deprotonation (4). Asn121 was mutated into serine
in DdahB and MlghB to test its involvement in 4-keto group binding. Based on the
enzymatic analysis, Asn121 is not essential for the catalysis of DdahB or MlghB on
hexose or mannose-based substrates (Figure 21,23). However, Asn121 involvement in
the substrate 4-keto binding cannot be interpreted by testing the current mutant, as the
substitution into serine could be conserving the function by interacting with the 4-keto
through the hydroxyl group. Another mutation where the Asn121 is mutated into a
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residue with a non-polar side chain, such as alanine, can be proposed to test the Asn
function.
A histidine-aspartate catalytic diad is conserved among the hexose-based
epimerases (RmlC) in many gram-negative bacteria (45, 63). It is important for C3 and
C5 epimerization as found in S. enterica’s and S. suis’s RmlC. It has been shown that in
such His-Asp diad, the aspartate role is to increase the basicity of the histidine to aid the
catalysis. However, the histidine still could function in the absence of the aspartate
although with less activity (45, 63). The His67-Asp173 diad was found in both DdahB
and MlghB. However, based on the crystallography of DdahB, the Asp173 was away
from the His67 and it was not conserved in the location compared to its location in
MlghB (Figure 14). The difference in the structure could explain the inability of DdahB
to function like MlghB under the same conditions to perform C5 epimerization. This can
be further addressed by mutating the Asp173 in MlghB into a non-functional residue to
see if MlghB will lose its C5 epimerization function.
The His67 was predicted as the catalytic residue for C3 epimerization in DdahB
and it was mutated into asparagine or alanine. DdahB H67A and H67N were significantly
less active than the wild type (Figure 21). The loss of activity indicates that the His67 is
involved in C3 epimerization, yet there is another residue that can perform this function.
In MlghB, the His67 was predicted to be catalytic for C3 and C5 epimerization. Mutating
the His67 into alanine or asparagine resulted in complete loss of the epimerization
function at C5. No C5-epimer (P4β) or C3/C5-epimer (P4γ) were detected even at longer
incubations as shown by the kinetics. Nevertheless, both mutants, H67A and H67N were
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poorly able to epimerize at C3 generating significantly less P4α than the wild type. These
data indicate that His67 is the catalytic residue for MlghB’s C5 epimerization. Consistent
with the His67 mutant’s analysis in DdahB, the slight C3 epimerization activity detected
in MlghB His67 mutants indicates that His67 is involved in C3 epimerization, but there is
another functional residue performing the epimerization at C3.
On GDP-mannose, the hexose-based substrate, both H67A and H67N of MlghB
were catalytically inactive, even at longer incubations as shown by the kinetics (Figure
23). In RmlC, which utilizes a hexose-based substrate generating a single C3/C5-epimer,
mutating the corresponding histidine resulted in inactivation of the enzyme. Therefore, it
is possible that MlghB is functioning like RmlC when utilizing a hexose-based substrate
by generating a single product. The loss of MlghB hexose-based product (P4’) upon
mutating the histidine indicates that P4’ could be a C3/C5-epimer.
The Tyr134 was predicted as a catalytic residue for C3 and C5 epimerization
and it was mutated into phenylalanine to test the function of the hydroxyl group in the
catalysis. The data only showed the activity of MlghB Y134F but not DdahB Y134F,
because the DdahB Y134F mutant was not generated at the onset of this experiment.
Surprisingly, MlghB Y134F mutant was catalytically active. However it showed
significantly less P4α and P4β compared to the wild type (Figure 21). The fact that P4γ
production was not affected could be explained by the preferable interconversion towered
P4γ. The formation of all epimerized products indicates that Tyr134 is not essential for
C3 or C5 epimerization.
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On GDP-mannose substrate, MlghB Y134F mutant was significantly less active
than the wild type (Figure 23). The poor activity of MlghB Y134F indicate that the
Tyr134 is not essential for catalysis. The structural modeling of the Y134F mutant
suggested that the compensation for the mutated Tyr134 function in MlghB Y134F could
be done by an adjacent Tyr132. A change in the orientation of Tyr134 was observed in
Y134F model compared to the wild type (Figure 12). The same change was also observed
in the N121S mutant, indicating that Y132 could have a flexible conformation of its side
chain. To investigate whether Tyr132 is compensating for Tyr134 function in the
catalysis of MlghB, or whether it is a catalytic residue, the single mutant Y132F, and the
double mutant Y134F/Y132F were generated for DdahB and MlghB by an M.Sc
candidate (Chelsea Kubinec). The activity of these mutants is under investigation.
Another function is predicted for Tyr132 based on the structure of DdahB and
MlghB. Tyr132 and His123 are aligned with conserved aromatic residues in RmlC
enzymes, usually Phe/Phe pairs (Figure 11). Thus, Tyr132 and His123 could function in a
stacking interaction with to physically stabilize the substrate during catalysis.
The Lys74 was predicted as a catalytic residue for C3 epimerization. Based on
the structure of DdahB and MlghB, Lys74 was the only residue that could function as a
base on the upper face of the active site. Therefore, it could deprotonate the substrate at
C3 from the upper face of the sugar ring. As shown in RmlC, the corresponding lysine
was essential for C3 epimerization (45, 55). The mutation of Lys74 into alanine has been
created for both DdahB and MlghB but the enzymatic activity of the mutated enzymes is
under investigation.
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The Gln85 was predicted to be involved in catalysis. Gln85 could not be directly
involved in the epimerization because it is located at the end of the active site on the
sugar-ring side (Figure 15-C). Nevertheless, it could be stabilizing an adjacent catalytic
residue that is involved directly in catalysis. Gln85 may perhaps be interacting with the
Asn121 through the amide group by a hydrogen bond (21, 63).
In conclusion, the role of Asn121 in the 4-keto group recognition of DdahB’s and
MlghB’s substrates is still unknown. In order to address that, mutating the Asn121 into a
residue with non- polar side chain is needed. The His67 is the catalytic residue for MlghB
C5 epimerization. The Asp173 is forming a diad with His67, and it could be essential for
C5 epimerization in MlghB. DdahB Asp73 is not conserved in its location in the
structure. Therefore, DdahB cannot perform C5 epimerization. His67, by itself, is
involved in C3 epimerization of both MlghB and DdahB, but there is another residue
performing C3 epimerization. Lys74 could be the catalytic residue for C3 epimerization
based on the structure. The Tyr134 is involved in C3 and C5 epimerization in MlghB,
and C3 epimerization in DdahC, yet it is not essential. Tyr132 could be a catalytic
residue, or it could compensate for the Tyr134 function in catalysis. Gln85 could be a
secondary catalytic residue that is interacting with Asn121 to aid the catalysis. The cocrystallography of DdahB and MlghB with their GDP-manno-heptose substrate will
increase our understanding of the residues’ function in the active site.
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4.3.

The substrates and products specificity of the reductases:

DdahC and MlghC are highly specific in their choice of the substrate and in their
products formation. The specificity of DdahC and MlghC toward their substrate was
investigated previously by providing the three epimerized substrates in the reaction (111).
DdahC only reduces the C3 epimer (P4α) that is generated by DdahB at C4 in an
NADPH-dependent manner to generate the final product GDP-6-deoxy-D-altro-heptose
(P5α). DdahC can also use the same P4α that is generated by MlghB C3 epimerization
generating the same product P5α. DdahC does not use the P4β or P4γ generated by
MlghB. In vitro, MlghC reduces the double epimer (P4γ) that is generated by MlghB.
The reduction occurs at C4 in an NADPH-dependent manner to generate GDP-6-deoxyL-gluco-heptose (P5γ) (111).
DdahC and MlghC also have specificity toward GDP-manno-heptose substrates
rather than GDP-mannose substrates. Using dehydrated GDP-mannose substrate (P1’)
and/or the epimerized form (P4’) to investigate the specificity of the reductases showed
that both DdahC and MlghC are less efficient in utilizing these substrates compared to
GDP-manno-heptose substrates. The analysis also showed that DdahC and MlghC can
use both P4’ and/or P1’. By using each of these substrates, DdahC generates two
products, PII and PIII, while MlghC generates one product, PI. The nature of these
products whether reduced or epimerized is unknown. Because DdahC and MlghC possess
the functional residues necessary for the epimerization, they could be functioning
differently when utilizing a hexose-based substrate by performing an epimerization
reaction. Unlike their activity in GDP-manno-heptose modification, where they only
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reduce an epimerized substrate, they could be epimerizing the dehydrated GDP-mannose
(P1’) then reducing it just like other hexose-based substrate C3/C5 epimerases, C4
reductases, such as GFS. The fact that the generated products for DdahC or MlghC from
P1’ and P4’ are the same suggest that they could be reducing the newly epimerized
P1’and the already epimerized P4’ into the same products. Unfortunately, it is difficult to
identify the nature of these products by mass spectrometry coupled with deuterium
incorporation due to their instability and the extremely low yields.

4.4.

Substrate binding and catalytic site of the reductases:

DdahC and MlghC overall structure indicates that both are members of the SDR
family (79). They have two domains, the co-factor binding domain and the substrate
binding domain. The residues that bind the NADPH in the co-factor binding domain are
found conserved with other SDR members and they were not discussed for simplicity.
Based on sequence alignment and the modeling, a set of hydrophobic residues forming
the binding pocket for GDP was identified (Table 4). Based on co-crystallography of
GFS and its substrate, a tryptophan residue is functioning as a gate to the substrate
binding site as it moves after binding to cover the substrate (99, 157). Therefore, the
corresponding tryptophan in DdahC and MlghC could be functioning in a similar fashion.
Based on the comparative functional analysis and the modeling, two residues
were predicted to interact with the sugar ring, Asn166 and Thr109 in DdahC, Asn165 and
Gly108 in MlghC, however, their role in catalysis is unknown. The residues that catalyze
the reduction activity of DdahC and MlghC have been identified. DdahC possesses the
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SYK catalytic triad that found in GFS, Ser108, Tyr137, and Lys141, while MlghC
possesses SMK catalytic triad, Ser106, Met110, and Lys139, similar to what has been
identified in a UDP-GlcNAc C4,6-dehydratase, WpbM (39, 40, 99). On the other hand,
aligned with the residues that were predicted to catalyze epimerization activity in GFS,
Cys109 and His170, DdahC had His180 and Thr110, while MlghC had Arg181 and
Tyr109. In this study, the residues His180 and Thr110 in DdahC have been targeted for
mutagenesis studies for two reasons. The first is that DdahC and MlghC are known to
perform NADPH-dependent reduction but not epimerization reactions. The second is that
theses residues are not conserved in both enzymes, which suggest their involvement in
the substrate and/or the product specificity.
The Thr110 was mutated into cysteine to mimic GFS catalysis by performing an
epimerization activity or by reducing a double epimer. The DdahC T110C mutant did not
change its substrate and it generated the same product as the wild type, P5α, although it
was faster and generated 50% more P5α than the wild type (Figure 25). This indicates
that Thr110 is not involved in the substrate or the product specificity on GDP-mannoheptose. The cysteine in DdahC T110C could have reduction potential resulted in
increasing the activity of DdahC.
Based on the available data for the activity on GDP-mannose, DdahC T110C
mutant was slower than the wild type (Figure 30-A) (Figure 26-A). The differences in the
catalysis rate of DdahC T110C on GDP-manno-heptose versus the activity on GDPmannose indicate that Thr110 confers specificity to the substrate whether heptose-based
or hexose-based substrate
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The His180 was mutated into arginine in DdahC to mimic MlghC’s substrate
specificity by reducing the double epimer P4γ. However, the DdahC H180R mutant did
not change its substrate, which is the C3-epimer P4α, and it generated the same product
as the wild type in a similar amount (Figure 25). On GDP-mannose, the DdahC H180R
mutant showed similar activity to the wild type. His180 perhaps is not important for the
substrate specificity or the reduction activity of DdahC. However, it is possible that
mutating the His180 into arginine does not affect the function simply because both the
histidine and the arginine have nitrogen on their side chain.
The double mutant H180R/T110Y that was generated to mimic MlghC’s
reduction of P4γ was catalytically inactive (Figure 25). Because the single H180R mutant
was active and comparable to the wild type, the mutation of the Thr110 into tyrosine
could be the reason of inactivation. When Thr110 was mutated into cysteine, DdahC
gained catalytic efficiency, while when Thr110 was mutated into tyrosine DdahC lost its
function. This suggests that Thr110 is a critical amino acid for DdahC activity. The
choice of a substitution to Thr110 is very important and is affecting the activity
differently. The exact role of the Thr110 in DdahC cannot be identified based on these
substitutions as they were chosen to mimic the catalysis of other enzymes. To address if
Thr110 has a role in the reduction activity of DdahC, Thr110 needs to be substituted with
a residue with a non-functional side chain.
On GDP-mannose, the double mutant DdahC H180R/T110Y was unexpectedly
active, and it generated the same products as the wild type (Figure 29). This surprising
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finding suggests that if Thr110 has a role in catalysis, its function is specific for utilizing
GDP-manno-heptose substrates rather than GDP-mannose.
The Cys68 in MlghC was mutated into alanine to test its involvement in the
activity of MlghC. C68A mutant generated the same product as the wild type, but 10%
less. C68A mutant was slower than the wild type, and the product formation was 50%
less than the wild type at longer incubation (Figure 30). This suggests that Cys68 is
involved in promoting the catalysis rate, perhaps by binding to the co-factor or its
reduced form. Based on the modeling Cys68 is close enough to interact with the
nicotinamide ring of the co-factor.
In conclusion, testing the Thr110 and the His180 residues of DdahC showed that
these residues are not involved in the specificity toward the epimerized substrates of
GDP-manno-heptose. Nevertheless, Thr110 could be an important residue for DdahC
activity. The function of Thr110 needs to be further investigated regarding its
involvement in DdahC reduction activity. The choice of the substitution amino acid for
Thr110 has a significant impact on the activity of DdahC. Mutating the Thr110 into
cysteine resulted in an increase in the substrate utilization and catalysis rate on the
heptose-based substrate. However the same mutation resulted in a decrease in the
catalysis rate on a hexose-based-substrate. The type of the function performed by DdahC
T110C mutant whether an epimerization, a reduction, or both still needs to be
investigated. In MlghC, the Cys68 is involved in catalysis maybe by interaction with the
co-factor.
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To further investigate the active site specificity of DdahC and MlghC, the
catalytic triad that is essential for the reduction activity needs to be targeted for
mutagenesis. The difference in the catalytic triad in DdahB (SYK) versus MlghC (SMK)
could be related to the substrate and/or the product specificity.

4.5.

The involvement of the modified heptose of C. jejuni NCTC 11168 in biofilm

formation.
The role of the modified heptoses with regards to bacterial resistance to serum
and bile salt, adhesion and invasion to host cells, as well as chicken colonization has been
investigated in C. jejuni NCTC 11168 (184). The wild type C. jejuni NCTC 11168 and
the heptose biosynthesis mutants are perfect tools to test the involvement of the modified
heptoses in C. jejuni virulence in vitro for two reasons.The first is that C. jejuni NCTC
11168 possesses the modified heptose as a side branch of the CPS backbone. The
location of the modified heptose as a side branch makes it the outermost exposed
structure to the extracellular environment, thus suggesting the possible interaction of the
modified heptose with the host. The second is that disrupting the modified heptose
synthesis is not affecting the CPS backbone structure. Therefore, the virulence phenotype
of the mutant is related to the loss of the modified heptose as opposed to the loss of the
capsule. Four mutants were generated containing a knockout of each of the modified
heptose synthesis genes, wcaG::cat, mlghB::cat, mlghC::cat, and wcaG∆::cat. In this
study, these mutants, along with the wild type as a positive control and the capsule-less
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kpsM::kan mutant as a negative control, were used to investigate the involvement of the
modified heptose in C. jejuni NCTC 11168 biofilm formation.
It is important to address the physiological characteristics that could affect the
biofilm formation of the mutants to better analyse the differences in biofilm formation
compared to the wild type. All the heptose biosynthesis mutants lack the side branch
modified heptose as shown previously (184). In addition, the wcaGΔ::cat does not have
the modified heptose or any CPS modification including the MeOPN. With regards to the
motility and agglutination of the mutants, all the heptose biosynthesis mutants are motile
and no significance difference in the agglutination compared to the wild type(184). In
contrast, the kpsM::kan mutant expresses non-functional flagella and has significant
increases in agglutination forming cellular clumps (184). The growth rate of the mutants
compared to the wild type was also analysed. The heptose biosynthesis mutants grow
faster than the wild type, with the highest growth rate for wcaGΔ::cat mutant (184).
In this study, the biofilm formation of C. jejuni NCTC 11168 wild type and
mutants was tested under aerobic versus microaerobic conditions. The wild type C. jejuni
NCTC 11168 had significantly increased biofilm formation under aerobic conditions
(Figure 31). In contrast, the wild type biofilm were not increasing under microaerobic
conditions (Figure 32). This was consistent with other studies that showed that the same
strain of C. jejuni is making more biofilm under aerobic condition. The increase in
biofilm formation protects C. jejuni cells from the atmospheric oxygen and thus allowing
prolonged survival.
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The wcaG::cat mutant made significantly less biofilm at both conditions,
however, at late time points the amount of the biofilm had significantly increased. This
means that the loss of the modified heptose in wcaG::cat mutant results in defects in
biofilm formation. In addition, under microaerobic conditions where C. jejuni wild type
does not need to form more biofilm over time, the wcaG::cat mutant needed to, until it
reached the wild type levels. The same results were observed for the wcaGΔ::cat mutant.
The early biofilm formation in wcaGΔ::cat mutant was significantly less than the wild
type under both conditions. However, the biofilm formation had significantly increased
over time. The mlghC::cat mutant also had a significant reduction in biofilm formation
compared to the wild type, but only under an aerobic conditions. The biofilm formation
was also significantly increasing over time. However, in microaerobic conditions there
was no significant difference between mlghC::cat mutant and the wild type. Furthermore,
in contrast to the microaerobic wcaG::cat and wcaGΔ::cat mutants’ biofilm, the biofilm
of mlghC::cat mutant was significantly decreased over time. On the other hand, the
mlghB::cat mutant made significantly less biofilm than the wild type under aerobic
conditions, but comparable biofilm to the wild type under microaerobic conditions. There
was no change in the amount of biofilm made by mlghB::cat mutant in both conditions.
In conclusion, under aerobic condition, the biofilm formation by wild type C.
jejuni NCTC 11168 is increasing. The modified heptose is important for C. jejuni NCTC
11168 biofilm formation. The biofilm formation of wcaG::cat, mlghC::cat, and
wcaGΔ::cat mutants were significantly increasing over time just like the wild type, yet
significantly less in the amount. This indicates that the loss of the modified heptose in
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theses mutants could slow down the process of making the biofilm under aerobic
condition. On the other hand, mlghB::cat mutant’s biofilm was comparable to the
negative control and did not increase.
Under microaerobic conditions, the biofilm formation by wild type C. jejuni
NCTC 11168 is not increasing over time (Figure 32). This means that under favorable
conditions, C. jejuni does not need to increase biofilm formation. However, wcaG::cat
and wcaGΔ::cat mutants had a significant increase in the late biofilm formation. This
suggests that the loss of the modified heptose in these mutants is stressing the bacterial
cells and drives them to increase the formation of biofilm. The opposite is found in
mlghB::cat mutant, where the formation of biofilm had decreased over time. Because all
the mutants lack the modified heptose, similar phenotypes were expected. However, in a
previous phenotypic analysis the same mutants showed variation in the results. The
expression profile of these mutants was previously investigated and showed that deletion
of the modified heptose genes resulted in upregulation of other CPS modification genes,
especially in mlghC::cat and mlghB::cat mutants. This indicated that there are
transcriptional regulatory effects that could influence the functional properties of the
CPS. Complemented strains were generated previously for the mutants. However, they
were unfunctional due to the presence of a very strong internal promoter that resulted in
significant transcriptional differences within the CPS cluster.
4.6.

Future directions:
In terms of the enzymatic analysis and the kinetics, further investigations for the

epimerases’ and the reductases’ kinetics need to be done in order to assess the catalytic
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activity of the mutants on GDP-manno-heptose. The GDP-manno-heptose epimerases
and reductases active sites need to be further investigated by creating additional
mutations by site-directed mutagenesis. Totally inactive mutants are needed to be used as
a tool for enzyme/substrate co-crystallography. Having inactive mutant will allow
generating a better resolution of the enzyme/substrate complex to identify the residues
that bind directly to the substrate. A pure GDP-manno-heptose, as well as GDP-6-deoxy4-keto-D-lyxo-heptose substrates, will be used to soak the epimerase crystals for
crystallography. After having the structure of the enzyme/substrate complex, the data will
be used as basis to screen for inhibitors using chemical libraries and assess the inhibitory
effect of the candidates if there are any.

4.7.

Significance and biological implications:
In C. jejuni, the major cause of gastroenteritis in humans, the putative heptose

epimerases and reductases of 81-167 and NCTC 11168 strains can be potential
antimicrobial targets due to their involvement in C. jejuni virulence, such as biofilm
formation. This project is the first to identify the structure and the potential role of the
functional residues in the active site of theses enzymes. The identification of specific
structural and functional characteristics is fundamental for designing specific inhibitors.
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Appendix 1: Subcloning primers
Primer
name

Sequence ( 5’ – 3’)

MlghB P2

AGGGTCCATGGCAATAGAATTTGATATA

MlghB P3

GCGTCGGATCCTTATCCTTTATTTTTAGTTGCAA

DdahB P2

GCTGGATCCTTATCCTTTATTTTTAGTTGCT

DdahB P3

CTCACATGTCCATGGCAATAGAATTTAATATAC

Restriction sites are in bold and underlined
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Appendix 2: SDM primers
Gene

Mutation

Primers Sequence ( 5’ – 3’)

Epimerases
Asn121Ser*

F:GTGCCAGCAGGTTTTGGAAGCGCTCATTATGTT
ACT AGTG
R:CACTAGTAACATAATGAGCGCTTCCAAAACCT
GCTG GCAC

His67Ala

F:CAATGTTATTCGCGGTATCGCTGGTGATGTAAA
AA CTTATAAGCTTG
R:CAAGCTTATAAGTTTTTACATCACCAGCGATAC
CG CGAATAACATTG

His67Asn

F:CAATGTTATTCGCGGTATCAATGGTGATGTAAA
AAC TTATAAGCTTG
R:CAAGCTTATAAGTTTTTACATCACCATTGATAC
CGC GAATAACATTG

Lys74Ala

F:CCATGGCGATGTAAAAACTTATGCGCTTGCAAC
TTG TGTTTATGG
R:CATAAACACAAGTTGCAAGCGCATAAGTTTTT
ACAT CGCCATGG

Asn121Ser*

F:ATTACCACCAAATATGGGAAGCTCTCATTATGT
GAG TTCAAAG
R:CTTTGAACTCACATAATGAGAGCTTCCCATATT
TGGT GGTAAT

His67Ala*

F:CCCATTTTAATGTTTTACGTGGAATAGCCGGAG
ATGT GAAAACTTAC
R:GTAAGTTTTCACATCTCCGGCTATTCCACGTAA
AACA TTAAAATGGG

His67Asn

F:CCCATTTTAATGTTTTACGTGGAATAAACGGAG
ATG TGAAAACTTAC
R:GTAAGTTTTCACATCTCCGTTTATTCCACGTAA
AACA TTAAAATGGG

Tyr134Phe*

F:CAAAGGAAGCAGTGTATTATTTTAAACTTGCTT
ATGA GGGG
R:CCCCTCATAAGCAAGTTTAAAATAATACACTGC
TTCC TTTG

Tyr132Phe**

F:GAGTTCAAAGGAAGCAGTGTTTTATTATAAACT
TGCTTATG
R: CATAAGCAAGTTTATAATAAAACACTGCTTCC
TTTGAACTC

DdahB

MlghB
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Lys74Ala

F:CACGGAGATGTGAAAACTTACGCACTTGTAACT
TGTG TCTATGGAG
R:CTCCATAGACACAAGTTACAAGTGCGTAAGTTT
TCAC ATCTCCGTG

Reductases

DdahC

MlghC

His180Arg*

F:GACAAATTTGATCTTGAAAAATCTCGTGTATTG
CCTGG AATTTTA AGAAA AATG
R:CATTTTTCTTAAAATTCCAGGCAATACACGAGA
TTTTT CAAGATCAAA TTTGTC

Thr110Tyr

F:GCTACTTTTCATAGCTTCAACTTACGTTTATCCT
AAAA ATGCAACATTG
R:CAATGTTGCATTTTTAGGATAAACGTAAGTTGA
AGCT ATGAAAAGTA GC

His180Arg/
Thr110Tyr*

Both His180Arg and Thr110Tyr

Thr110Cys*

F:CTACTTTTTTCATAGCTTCAACTTGCGTTTAT
CCTAA AAATGCAAC ATTG
R:CAATGTTGCATTTTTAGGATAAACGCAAGTTGA
AGC TATGAAAA AAGTAG

Cys68Ala*

F:GACTGCAGTCTTACCTGCTGGTGCTGCAAATGT
CG
R:CGACATTTGCAGCACCAGCAGGTAAGACTGCA
GTC

*SDM done by Michael Roubakha, 2013
** SDM done by Chelsea Kubinec, 2015
F and R indicate forward and reverse primer respectively.
Mutated residues codons are in bold, and the mutated nucleotides are underlined.
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Appendix 3: Antibodies used for Western blot
Primary antibody
and dilution*

Epitope
detected

Secondary
antibody

Wavelength
detected (nm)

Monoclonal anti-His
(mouse), 1:5000

His6 Tag

Anti-mouse ( goat)
1:5000

700

Monoclonal antiGST (rabbit), 1:3000

GST Tag

Anti-rabbit ( goat)
1:2000

800

* Dilution was made in 1 PBS buffer and 0.05 % sodium azide.

170

Appendix 4: Integration data of the CE electropherograms for the epimerases
activity on GDP-manno-heptose:
The table shows the means of three independent experiments (Figure 21-A2,B2). The
products are represented by their order of appearance in the CE electropherograms. The
data represent the area of each peak in percentage to the total area of the sugar
nucleotides. The impurity and NADP+ peaks were excluded from the integration.
Enzyme

P4γ

DdahB H67N
DdahB H67A
DdahB N121S
DdahB WT
DdahA

0.0
0.0
0.0
0.0
0.0

MlghB Y134F
MlghB H67N
MlghB H67A
MlghB N121S
MlghB WT
DdahA

13.0
0.0
0.0
25.0
22.2
0.0

P1

P4β

(Percentage %)
88.8
0.0
90.0
0.0
70.6
0.0
63.7
0.0
100.0
0.0
(Percentage %)
74.4
6.4
93.1
0.0
89.2
0.0
35.7
29.0
28.8
25.6
100.0
0.0

P4α
11.2
10.0
29.4
36.3
0.0
8.3
6.9
10.8
20.0
31.9
0.0
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Appendix 5: Integration data of the CE electropherograms for the epimerases
activity on GDP-mannose:
The table shows the means of two independent experiments (Figure 23-B2). The products
are represented by their order of appearance in the CE electropherograms. The data
represent the area of each peak in percentage to the total area of the sugar nucleotides.
The GDP-mannose peak was excluded from the integration.
Enzyme
DdahB H67N
DdahB H67A
DdahB N121S
DdahB WT
MlghB Y134F
MlghB H67N
MlghB H67A
MlghB N121S
MlghB WT

P4’

P1’

(Percentage %)
0.0
100
0.0
100
0.0
100
6.5
93.5
(Percentage %)
10.1
89.9
0.0
100.0
0.0
100.0
43.0
57.0
42.2
57.9
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Appendix 6: Integration data for CE electropherograms shown in Figure 25
The traces and are represented in their order in the figure. The peaks are represented by
their order of appearance in the CE electropherograms. For panel A, the dada represent
the area of each peak in percentage to the total area of the sugar nucleotides. P4β peak
was excluded from the integration because of the poor resolution from NADP+. The
impurity peak was also excluded. For panel B, the data for the substrates and the
products peaks areas are represented in ratio to the impurity peak area (annotated as *),
assuming that all traces has the same amount of the impurity. The peak of NADP+ and the
co-migrated P4β were included in the integration. This was done in order to evaluate the
changes in the substrate specificity of the mutants. MlghB reaction trace could not be
used as a control. Instead, the inactive DdahC H180R/T110Y mutant was used as a
virtual control.
Trace

Enzyme

P5γ

P4γ

P1

P5α

P4α
16.4
18.4
39.6
18.7
16.7
21.5

Panel A
g
f
e
d
c
b

MlghC C68A
MlghC WT
DdahC H180R/T110Y
DdahC H180R
DdahC T110C
DdahC WT

56.7
63.4
0.0
0.0
0.0
0.0

(Percentage %)
9.3
17.5 0.0
4.9
13.2 0.0
25.9 34.5 0.0
21.7 24.2 35.4
17.2 20.1 46.0
23.2 24.2 31.1

Trace

Enzyme

P5γ

P4γ

Panel B
g
f
e
d
c
b

MlghC C68A
MlghC WT
DdahC H180R/T110Y
DdahC H180R
DdahC T110C
DdahC WT

0.45
0.87
0.00
0.00
0.00
0.00

0.95
0.62
1.22
1.21
1.25
1.37

P1

P5α

NADP+
P4β

(Ratio to *)
1.61 0.00 2.28
1.50 0.00 2.61
1.48 0.00 0.97
1.46 0.08 1.44
1.38 0.33 1.78
1.69 0.16 1.12

P4α

*

0.38
0.41
0.44
0.34
0.26
0.36

1.00
1.00
1.00
1.00
1.00
1.00
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